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Quercetin is a flavonoid commonly found in fruits and 
vegetables which exerts selective cytotoxicity on cancer cells 
and synergizes with chemotherapeutic drugs.  However, its 
clinical usage has been hampered by low water solubility. 
Therefore, the objectives of this thesis were to (i) develop a 
liposomal formulation to solubilize quercetin, (ii) identify 
chemotherapeutic drugs that synergize with quercetin in breast 
cancer cells,  (ii i)  co-encapsulate quercetin/drug combinations 
into liposomes, and (iv) evaluate the co-encapsulated 
formulation in vitro  and in vivo.  Liposomal encapsulation of 
quercetin was around 100%, increased its solubility by 10-fold, 
reduced quercetin degradation and the formulation was also 
physically stable.  Quercetin synergized with (i) irinotecan and 
(ii)  vincristine in the JIMT-1 and MDA-MB-231 breast cancer 
cell lines. Irinotecan could be encapsulated in DPPC/DSPE-
PEG20 00/Quercetin (90:5:5 mole ratio) liposomes  with around 
80% efficiency and vincristine could be encapsulated in 
ESM/Cholesterol/PEG2 000-ceramide/Quercetin (72.5:17.5:5:5 
mole ratio) liposomes with around 70% efficiency. Both 
formulations displayed controlled and co-ordinated release of the 
two agents.  In vitro  evaluation of liposomal vincristine/quercetin 
formulation comprising of ESM/Cholesterol/PEG2 000-





highest anti-cancer activity; thus, this formulation was further 
evaluated in vivo .   Through liposomal co-encapsulation, plasma 
half lives of quercetin and vincristine were increased, and the 
synergistic ratio of the two drugs maintained.  The formulation 
exhibited significant anti-tumor activity at two-thirds of the 
maximum tolerated dose of vincristine in a human epidermal 
growth factor 2 overexpressing, trastuzumab-resistant breast 
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Drug delivery systems have been shown to improve the 
pharmacological properties of many drugs, resulting in increased 
circulation lifetimes, enhanced efficacy and reduced toxicity 
(Papahadjopoulos, Allen et al.  1991). Recently, drug delivery 
systems, such as liposomes (Zamboni 2005; Lee, Kim et al.  2006; 
Fanciullino and Ciccolini 2009), micelles (Koo, Rubinstein et al.  
2006; Kedar, Phutane et al.  2010), and nanoparticles (Langer, 
Balthasar et al.  2003; Wang, Sui et al.  2010) have been used for 
systemic delivery of anti-cancer agents, enhancing the efficacy 
and ameliorating the toxicity of chemotherapeutic drugs. 
Therefore, this project aims to develop and characterize a drug 
delivery system for a natural product, quercetin, and to co-
encapsulate conventional chemotherapeutic agents exhibiting 
synergism with quercetin so as to develop effective and novel 
treatment regimens against cancer. 
 
1.2 Cancer overview 
 
The National Cancer Institute defines cancer as a disorder 





invade other tissues. Cancer development is a multi-step process 
which involves a series of gene mutations leading to gradual 
increases in tumor size, disorganization and malignancy 
(Vogelstein and Kinzler 1993). Due to the many different 
possible gene mutations, cancer is not a single disease but a 
group of diseases that differ in prognosis and response to 
treatment. Nevertheless, cancer cells have seven common 
characteristics, which are  self-sufficiency in growth signals, 
insensitivity to antigrowth signals, evasion of apoptosis, 
l imitless replicative potential,  sustained angiogenesis, tissue 
invasion and metastasis (Hanahan and Weinberg 2000). 
Globally, cancer is the leading cause of death, accounting 
for 7.9 million deaths, which constitute approximately 13% of all  
deaths (World Health Organization, Global cancer statistics, 
2007). In addition, deaths from cancer are projected to continue 
rising to an estimated 12 million in 2030 worldwide. Of all  
cancers, breast cancer is the most common in women, with an 
estimated 1.15 million new cases worldwide annually and also 
the leading cause of cancer mortality in women (Parkin, Bray et 
al.  2005). Locally, the breast cancer incidence and mortality 
rates reflect these global trends as well  (Singapore Cancer 
Registry Report,  2008). Despite their high prevalence and 
mortality rates, current treatment regimens for breast cancer 
remain unsatisfactory. The relapse rate for  breast cancer patients 





need for the continued research to develop and improve treatment 
regimens against breast cancer. 
  
1.3 Treatment regimens against breast cancer 
 
Surgery and radiation are often used to treat early stage 
localized breast cancer. Besides surgery and radiation, additional 
treatment modalities include endocrine and biological therapy. 
Endocrine therapy with tamoxifen or aromatase inhibitors such 
as letrozole, anastrozole and exemestane are used in tumors 
expressing either estrogen and/or progesterone receptors. In 
addition, biological therapy with trastuzumab is used in tumors 
overexpressing human epidermal growth factor receptor 2 
(HER2). With the advert of endocrine and biological therapy, 
tumors expressing estrogen, progesterone and HER2 receptors 
have better prognosis as compared to breast cancer subtypes that 
do not express these receptors (Dizdar and Altundag 2010; 
Keshtgar, Davidson et al.  2010).  
Chemotherapy is the cornerstone therapy for advanced 
breast cancer, especially for breast cancers that do not express 
estrogen, progesterone and HER2 receptors. In addition, 
chemotherapy is not only given for the treatment of systemic 
disease, i t  can also be given before surgery to reduce tumor size 
(neoadjuvant chemotherapy) or after surgery or radiation 





endocrine or biological therapy to reduce the chance of relapse 
and to improve overall  survival.   Despite the principal role of 
chemotherapy in cancer treatment,  current treatment regimes 
remain suboptimal due to the narrow chemotherapeutic index of 
the anti-cancer agents, which limits the dose that can be given. 
Hence, there is great interest in investigating ways to reduce the 
toxicity and increase the efficacy of chemotherapeutic agents. 
 
1.4 Quercetin overview 
 
Quercetin (Figure 1) is the most common flavonoid present 
in many fruits and vegetables (Casagrande, Georgetti  et al.  
2006). It  is non-toxic and has been administered with oral doses 
of 4g without side effects (Lamson and Brignall 2000). It  has a 
wide range of biological actions, such as antioxidant (Saija, 
Scalese et al.  1995; Ratnam, Ankola et al.  2006), anti-
inflammatory (Gonzalez-Gallego, Sanchez-Campos et al.  2007) 
and antiviral activities (Cushnie and Lamb 2005). In addition, 
recent epidemiological studies have described the beneficial  
effects of dietary flavonoids in the reduction of cancer risk 
(Ramos 2007), leading to great interest in the use of flavonoids 








Figure 1 Structure of quercetin. 
 
Recent in vitro  studies have shown that quercetin exhibits 
antiproliferative activities in a wide range of cancers such as 
colon cancer (van der Woude, Gliszczynska-Swiglo et al.  2003), 
breast cancer (Hakimuddin, Paliyath et al.  2004), ovarian cancer 
(Ferry, Smith et al.  1996), prostate cancer (Chowdhury, Kishino 
et al.  2005) and lung cancer (Hung 2007).  Quercetin exerts its 
antiproliferative effects through the inhibition of the PI3K-
AKT/PKB pathway (Gulati,  Laudet et al.  2006), downregulation 
of the expression of oncogenes and anti-oncogenes (Ranelletti ,  
Maggiano et al.  2000), upregulation of cell  cycle control proteins 
(Casagrande and Darbon 2001), inhibition of heat shock proteins 
(Sliutz, Karlseder et  al .  1996), inhibition of tyrosine protein 
kinases such as epidermal growth factor receptor (EGFR) (Lee, 
Huang et al.  2002) and  HER2 (Jeong, An et al.  2008) and 
through its interaction with Type II estrogen binding site 
(Scambia, Ranelletti  et al.  1990). In addition, quercetin has been 







without affecting normal cells (Chowdhury, Kishino et al.  2005). 
As a consequence, there has been great interest in combining 
quercetin with conventional chemotherapeutic agents to enhance 
their therapeutic activities.  
 
1.5 Methods to determine synergy 
 
Combinations of chemotherapeutic agents can act in a 
synergistic, additive or antagonistic manner. Synergism occurs 
when the combined activities of the drugs are greater than 
predicted from the individual contribution of the individual 
drugs and antagonism occurs when the effect of combination is 
less than the sum of activities of the individual agents. 
Therefore, there is a need to evaluate whether the combination is  
synergistic, additive or antagonistic. In this Section, three of the 
most commonly used methods to determine synergy will  be 
discussed. These methods are the isobologram (Loewe 1957; 
Steel and Peckham 1979), surface response analysis (Bliss 1939) 
and the median-effect principle (Chou and Talalay 1977). 
In classical isobologram (Figure 2a), the concentrations of 
each drug, when used alone to attain a specific effect are plotted 
on the x and y  axes on a graph (Loewe 1957). A line, called the 
line of additivity, is used to connect these two points. 
Subsequently, the concentrations of the drugs used in 





Synergy, additivity, or antagonism occurs when this point is 
located below, on, or above the line respectively.  
The advantages of the classical isobologram method are that 
the isobologram is easy to plot and synergy, additivity or 
antagonism can be easily visualized from the graph. However, 
the disadvantages of this method are that it  requires many 
experiments to attain the data needed to plot the isobologram, 
can only be used for fixed ratio drug combinations and fails to 
quantify the extent of synergism or antagonism.  
In view of the disadvantages, Steel and Peckham further 
refined the classical isobologram method by developing an 
envelope of additivity which is enclosed within the boundaries of 
mode I and II curves in the isobologram (Figure 2b). The mode I 
curve is created by plotting a given dose of drug A against the 
dose of drug B needed to produce an effect equal to the 
difference between the chosen cytotoxic effect and the effect of 
the current dose of drug B. The mode II curve is generated by 
plotting the dose of drug A against the dose of drug B needed to 
increase the effect of drug B to the chosen effect level.  For both 
modes, doses of drugs are varied to obtain a curve. Finally, the 
combination data obtained from experiments are plotted on the 
graph. Combinations of drugs that produce additive effects lay 
within the boundaries of Mode I and II,  while combinations 
which produce effects displaced to the left  are synergistic and 





advantage of this method is that the envelope of addivity helps to 
gauge whether the difference in addivity is large enough to 
warrant further investigation. Despite this,  this method shares 
the other disadvantages of the classical isobologram, which are 
the large amount of data necessary to plot the graph and can only 
be used for fixed ratio drug combinations. 
 Another commonly used method is surface response 
analysis (Bliss 1939). In this method, the doses are plotted on 
the x and y axes and the effect are plotted on the z axis.  Many 
different doses and effects are plotted on the 3 dimensional 
graph and a smooth surface representing the additivity of the 
combination is plotted (Figure 2c).  A combination with values 
that are above the surface indicates a synergistic effect and an 
effect below this indicates antagonism. When a fixed ratio of 
drug combination is being used,  
A = a + rab, 
where A is the additive effect,  a and b are the doses of Drug A 
and B used in combination and ra is the ratio of drug A: B.  
Subsequently,  
α  = O/A 
Where α  represents the interaction index, O represents the dose 
of drug A to attain the observed effect obtained from the surface 
response graph. If α  is less than one, there is synergism and if α  





The advantages of this method are that it  gives a 
quantitative response which can be used to gauge and compare 
the extent of synergism of different drug combinations and 
doses. However, this method requires a complicated experimental 
design to obtain the large number of data points necessary and it  
is difficult  to visualize the data points on the three dimensional 
graph.   
The last method discussed here is the median-effect 
principle. In the median-effect principle, the dose of drug is 
correlated with cytotoxicity by the median-effect equation:  
   fa  /  fu  = (D/Dm)m or its alternative form,  
D = Dm[ fa /  (1 – fa)]1 / m 
This equation is linearized,  
         log (fa /  fu) = m log (D) – m log Dm  
        and plotted as the median-effect plot,  
where fa refers the fraction affected by the dose, fu is the fraction 
unaffected (fu = 1 – fa),  D is the dose of the drug, Dm is the 
median-effect dose signifying the potency which is determined 
from the x-intercept of the median-effect plot.  The value m is an 
exponent that signifies the sigmoidicity of the dose-effect curve, 
which is determined by the slope of the median-effect plot. In 
addition, the linear correlation coefficient r of the median-effect 
plot indicates the goodness of fit  of the data to the equation. 
For two drugs in which the effects of both drugs are 





drugs and their drug combinations) and for drugs whose effects 
are mutually nonexclusive (non parallel  median-effect plots for 
the drugs and their combinations), the general equation is: 
[(fa)1 , 2  /  (fu)1 ,2]1 / m  
= [(fa)1  /  (fu)1]1 / m + [(fa)2  /  (fu)2]1 / m + [(fa)1(fa)2 /  (fu)1(fu)2]1 / m 
= (D)1 /  (Dm)1 + (D)2 /  (Dm)2 + (D)1(D)2 /  (Dm)1(Dm)2 
Therefore, for mutually exclusive drug combinations, 
CI = (D)1  /(Dx)1  + (D)2  /(Dx)2 
And for mutually non exclusive drug combinations,  
    
CI = (D)1  /(Dx)1  + (D)2  /(Dx)2  + (D)1(D)2/(Dx)1(Dx)2  
 
where CI refers to the combination index,  Dx which is the dose 
of a drug that inhibits “x” percent of cells.  
In this equation, synergism is defined as a greater-than-
the-expected-additive effect,  and antagonism is defined as less 
than-the-expected-additive effect.  Thus, CI = 1 indicates an 
additive effect,  CI < 1 indicates a synergistic effect,  and CI > 1 
indicates antagonism. The precise significance of various degrees 
of synergism or antagonism has been proposed that to be 
interpreted as follows: 
Table 1 Interpretation of combination index values generated by 
the median-effect equation.    
<0.1 very strong synergism 
0.1–0.3  strong synergism 
0.3–0.7 synergism 
0.7–0.9 moderate to slight synergism 
0.9–1.1 nearly additive 
1.1–1.45 slight to moderate antagonism 
1.45–3.3 antagonism 






In this work, median-effect equation is used to evaluate 
synergy as it  is a flexible method which can be used to determine 
synergy when the drug combination is in a fixed ratio or when 
the drug combination is in a non-fixed ratio, where the dose of 
one drug is fixed and the other is varied. Most importantly, this 
method has biological relevance and the in vitro  results have 
been shown to correlate whether the combination would work in 
a synergistic or antagonistic manner in vivo  (Abraham, McKenzie 



























Figure 2 Representative plots illustrating (a) classical 
isobologram, (b) Steel and Peckham isobologram, reprinted with 





concurrent chemoradiation paradigm general principles” by 
Seiwert et al. ,  1969 and (c) surface response analysis. Reprinted 
with permission from Elsevier Limited, Leukemia Research “In 
vivo  maintenance of synergistic cytarabine:daunorubicin ratios 
greatly enhances therapeutic efficacy”, Tardi et al. ,  2009.  
 
1.6 Synergism of quercetin with conventional chemotherapeutic drugs 
 
Synergism can occur when the compounds act on different 
pathways which interact and lead to synergy (Shah and Schwartz 
2001) or from the direct interaction of the compounds on 
different stages of the same pathway (Dancey and Chen 2006). 
Besides the mechanism of action, the efficacy of the anti-cancer 
activity of chemotherapeutic agents is also drug ratio dependent, 
exhibiting synergism at certain ratios but additivity or 
antagonism at other ratios (Mayer, Harasym et al.  2006; 
Harasym, Liboiron et al .  2009; Tardi, Johnstone et al.  2009). 
However, this effect has not been extensively researched because 
when drugs are administered, the synergistic ratio may not be 
maintained due to the variations in the different pharmacokinetic 
profiles of the individual drugs. Table 2 summarizes the 
synergism of quercetin with several chemotherapeutic agents and 
the mechanism of synergy.  
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Table 2 Summary of the synergism of quercetin with chemotherapeutic agents. 




Carboplatin Human Hepatoma cell 
line Hep 3B and Hep 
G2  
Quercetin potentiates the action of carboplatin 
by inhibiting heat shock proteins (Sharma, 
Upadhyay et al .  2009).  
 
 Cisplatin Human ovarian 
cancer  OVCA 433 
cells 
 
Quercetin synergized with cisplatin by acting 
through an interaction with Type II estrogen 
binding site (Scambia, Ranelletti  et al.  1990). 
  Human ovarian 
cancer CAOV3 and 
SKOV3 cells 
Addition of quercetin increased sensitivity of 
the cells to cisplatin through the inhibition of 
interleukin 6 (Chan, Fong et al .  2003). 
 
  Human laryngeal 
cancer Hep 2 cells 
The combination of quercetin and cisplatin 
acted on complementary pathways, increasing 
the percentage of cells undergoing apoptosis. 
Quercetin inhibited Akt/PKB phosphorylation 
while cisplatin induced JNK activity and 
increased caspase 9 (Sharma, Sen et al.  2005).  
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Topotecan Murine fibrosarcoma 
cell l ines  
 
Quercetin inactivated hsp 70, thereby 
sensitizing the cells to topotecan (Sliutz, 
Karlseder et al.  1996). 
 
  Human breast cancer 
cells MCF-7 & MDA-
MB-231 
Quercetin enhanced the effects of topotecan by 
inhibiting the activities of tyrosine-specific 
protein kinases (Akbas, Timur et al.  2005). 
 
 Irinotecan Human and rat liver 
microsomes 
Quercetin inhibited the metabolic inactivation 




Vincristine Human cervical 
cancer cells MRP1-
transfected HeLa T5 
Quercetin inhibited the ATPase activity of 
MRP1 (Multidrug Resistance Protein 1),  
thereby increasing vincristine levels in the 




5 fluorouracil Human colon cancer 
cells 
DLD-1 colon cancer 
cells 
Co-administration of quercetin and 5 
fluorouracil markedly inhibited thymidylate 
synthase and survivin expression as compared 
to the individual administration of each single 
agent (Nakayama, Sakamoto et al.  2000). 
15  
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Table 2: Continued 
    
Other agents Carboxytriazole Human breast cancer 
cell  MDA-MB 435 
Quercetin depressed IP3 levels that decreased 
the cytosolic calcium concentration while 
carboxytriazole inhibits calcium influx into 
cells (Yeh, Herenyiova et al.  1995). 
    
16 
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1.7 Barriers to the adoption of quercetin in the clinical setting 
 
Although quercetin has been shown to have 
antiproliferative effects in vitro ,  the median effective 
concentration is around 80 µM (van der Woude, Gliszczynska-
Swiglo et al.  2003; Goniotaki, Hatziantoniou et al.  2004). In 
contrast,  the peak plasma quercetin concentration that can be 
attained, after quercetin supplementation triple that of the 
average daily intake, is only 0.5 µM (Hollman, Gaag et al.  1996). 
This represents around 100-fold difference from the median 
effective dose needed for anti-cancer activity. The low plasma 
quercetin concentrations could be attributed to its low water 
solubility of 80 μM (van der Woude, Gliszczynska-Swiglo et al.  
2003), which limits absorption (Hollman, Gaag et al.  1996). 
Hence, the concentrations used for in vitro studies cannot be 
attained by ingestion of quercetin alone (Hollman, Gaag et al. 
1996).  In addition, quercetin has been shown to be chemically 
unstable in physiological pH (van der Woude, Gliszczynska-
Swiglo et al.  2003). Therefore, the development of an 
appropriate carrier for quercetin can facilitate its clinical use. 
 
1.8 Pros and cons of current approaches to solubilize quercetin 
 
Parenteral administration of chemotherapy is the most 
common route in the treatment of disseminated cancers as the 
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administered drug could go to almost anywhere in the body 
through the bloodstream (Brunton and Lazo 2005). However, due 
to the low solubility of quercetin, it  has to be solubilized to 
prevent precipitation and emboli formation after intravenous 
administration (Joseph 1911). Therefore, many approaches have 
been attempted to improve quercetin solubility.  
One of the approaches to improve quercetin solubility is 
through the synthesis of water soluble prodrugs of quercetin. A 
glycine carbamate prodrug of quercetin (QC12) has been 
synthesized by Mulholland et al.  Despite improved water 
solubility, QC12 was not bioavailable when it  was administered 
orally and had a short half life of 0.31 h when administered 
intravenously (Mulholland, Ferry et al.  2001). Besides QC12, 
water soluble sodium sulfonic derivatives of quercetin have also 
been synthesized (Krol,  Dworniczak et al .  2002). Although these 
derivatives improved solubility, they were less potent than 
quercetin, suggesting that the cytotoxic activity of quercetin 
could be related to its l ipophilicity. Therefore, despite 
improvements in water solubility, there has been limited success 
with the prodrug approach in terms of half life prolongation and 
maintenance of the potency of quercetin.   
Besides chemical modification, drug carriers can also be 
used for the intravenous delivery of quercetin. Properties of an 
ideal drug carrier for parenteral administration include 
biocompatibility, non-toxicity, aqueous solubility, ability to 
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solubilize a considerable amount of drug, and the  ,  ability to 
release drug at a controlled rate and to prevent or slow down 
drug degradation (Leung, Robinson et al.  1987). In addition, 
since it  is of interest to co-encapsulate quercetin with 
conventional chemotherapeutic drugs, the drug delivery system 
should be able to co-encapsulate both hydrophobic and 
hydrophilic drugs in the same carrier. Another property that a 
drug carrier should possess is to be able to co-ordinate the 
release of quercetin with conventional chemotherapeutic agents 
in the optimal synergistic ratio to enhance anti-cancer activity, 
as only drug that is released from the carrier is active. 
Microemulsions, which are dispersions comprising of an oil 
phase, a water phase and surfactants have been developed for the 
solubilization and intravenous administration of quercetin 
(Gupta, Moulik et al.  2005). Although a quercetin microemulsion 
comprising of clove oil/Tween 20/water has been developed for 
intravenous administration of quercetin, improving its solubility 
by seven fold, the excipients used were found to be hepatotoxic 
and nephrotoxic following intravenous administration. Similarly, 
other microemulsions developed to solubilize quercetin were 
mainly preparations for topical (Kitagawa, Tanaka et al .  2009), 
oral (Gao, Wang et al.  2009) or inhalation use (Rogerio, Dora et 
al.  2010), which cannot be adapted directly for intravenous 
administration due to the toxicity of the excipients (Date and 
Nagarsenker 2008). Given the toxicity of the excipients used in 
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the formulation of microemulsions, this formulation may not be 
appropriate for intravenous formulation of quercetin.  
Besides microemulsions, the solubilization of quercetin with 
β-cyclodextrins has also been attempted (Zheng, Haworth et al .  
2005). β-cyclodextrins are cyclic (α-1,4)-linked oligosaccharides 
composed of seven α-D-glucopyranose units,  which together 
form a rigid cone shaped structure. Although quercetin was 
stabilized and solubilized around 200 fold, β-cyclodextrins have 
been associated with a risk of nephrotoxicity (Frijl ink, Eissens et 
al.  1991) and have low aqueous solubility (Szejtli  1991). These 
two factors hamper their use for parenteral drug delivery. 
Nanoparticulate delivery systems are solid colloidal 
particles, ranging in size from 1 to 500  nm, consisting of 
various polymeric matrices in which therapeutic moiety can be 
adsorbed, entrapped, or covalently attached (Uchegbu 1999). 
Quercetin nanoparticles comprising of polyvinyl alcohol & 
Eudragit® have been formulated. Although quercetin was 
efficiently encapsulated (up to 99%), in vitro studies showed that 
more than 95% of quercetin was released within 20 minutes (Wu, 
Yen et al.  2008). In addition, quercetin has also been 
incorporated in poly (D,L-lactideco-glycolide) nanoparticles together 
with vincristine. However, the encapsulation efficiency was 
suboptimal at 32.6% and rapid release of quercetin was also 
observed, with 70% of quercetin released over 3 hours (Song, 
Zhao et al.  2008). This rapid release from the carrier could 
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potentially prevent the accumulation of the anti-cancer drugs in 
tumor site via the enhanced permeability and retention (EPR) 
effect (Matsumura and Maeda 1986). Under the EPR effect,  
macromolecules with molecular weights larger than 40kDa (such 
as liposomes and other nanoparticulate systems) accumulate 
preferentially in the tumor tissue due to the abnormal 
architecture of the tumor blood vessels, which allow the escape 
of the macromolecules from the bloodstream and their 
accumulation in the tumor interstit ium. When the drug is rapidly 
released from the carrier,  i t  is unable to accumulate in the tumor 
interstitium through the EPR effect as the drug of low molecular 
weight leaks out from the tumor interstit ium back to the blood 
circulation quickly (Maeda 2002). Therefore, more optimization 
is needed to slow down the release of quercetin and to 
incorporate quercetin more efficiently in polymeric nanoparticles 
for parenteral use. Besides polymeric nanoparticles, quercetin 
has been solubilized in solid lipid nanoparticles (Li,  Zhao et al . 
2009). Although solid lipid nanoparticles are biocompatible and 
could also protect quercetin from degradation, solid lipid 
nanoparticles are limited by their inefficient encapsulation of 
hydrophilic and amphipathic drugs (Cai, Wang et al.  2010), 
hence they are not suitable for co-encapsulation of quercetin 
with hydrophilic or amphipathic  chemotherapeutic agents.   
Liposomes, which are small spherical vesicles formed by a 
lipid bilayer enclosing an aqueous compartment  (Bangham, 
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Standish et al.  1965), have been developed and their  
encapsulation efficiencies were close to 100% (Goniotaki,  
Hatziantoniou et al .  2004; Yuan, Chen et al.  2006; Priprem, 
Watanatorn et al.  2008). Due to their similarity with 
endogeneous substances in the body, liposomes are also 
biocompatible and non-toxic  (Bonte, Hsu et al.  1987). In 
addition, as compared to the other delivery systems, liposomes 
are the most successful in terms of translating into clinical trials 
and approval, with four products available on the market for 
cancer treatment (Table 3) and many liposomal formulations are 
currently undergoing clinical trials (Table 4).   
.   
Table 3 Marketed liposomal products for cancer treatment. 
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Table 4 Novel liposomal formulations under clinical trials for 
cancer. 
 
Component Indication Phase of 
clinical trial 
Liposomal BLP25 
(peptide derived from 
mucin 1) 
















Primary or metastatic 











Liposomal mitoxantrone  Advanced cancer Phase I 


























Metastatic or recurrent 
cancer of the 
endometrium or the 
lung 
Phase 1 
Liposomal cisplatin Recurrent ovarian 
cancer 
Phase II 
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Table 4 continued 
 
  
Liposomal daunorubicin  HIV-Related Kaposi 's 
Sarcoma 
Phase III 
Liposomal lurtotecan  Metastatic or locally 
recurrent head and 
neck cancer  
Recurrent small cell  
lung cancer 
Phase II 
Reference: clinicaltrials.gov assessed on 1s t  June 2010 
 
In addition, liposomes are also versatile drug delivery 
systems which can encapsulate hydrophobic, hydrophilic and 
amphiphilic compounds simultaneously. Furthermore, an 
appropriately optimized liposomal formulation can also release 
the encapsulated drug in a controlled manner (Dos Santos, 
Waterhouse et al.  2005), prolong the circulation time of the drug 
(Papahadjopoulos, Allen et al.  1991) and also accumulate 
preferentially in the tumor tissue through the EPR effect 
(Matsumura and Maeda 1986) so as to improve their therapeutic 
efficacy and reduce their toxicity profile. Finally, a liposome 
formulation has been shown to coordinate drug release and 
maintain the synergistic molar ratio of the two drugs for optimal 
anti-cancer activity (Harasym, Tardi et al.  2007). This is 
il lustrated by the combination of irinotecan and floxuridine and 
that of cytarabine and daunorubicin, which are currently in 
clinical trials (Table 4). In view of these advantages, l iposomes 
will be the drug delivery system explored in this thesis. 
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1.9 Classification of liposomes 
 
Liposomes can be classified according to the number of 
lipid bilayers and size. Multilamellar vesicles (MLVs) are large 
"onion-like" structures formed when the lipids are hydrated in 
aqueous solutions. They have diameters of around 1 μm. Small 
unilamellar vesicles (SUV) have a single bilayer surrounding an 
aqueous core. They are prepared from MLVs by sonication and 
have diameters between 15-30 nm. However, due to the high 
degree of curvature of the membrane, SUVs will spontaneously 
fuse to form larger vesicles upon storage. Like SUVs, large 
unilamellar vesicles (LUV) also have a single bilayer 
surrounding an aqueous core. The size of LUVs ranges from 100-
200 nm. LUVs can be prepared from MLVs by a variety of 
methods including extrusion and reverse phase evaporation 
(Szoka and Papahadjopoulos 1978). Extrusion, which is the 
process of passing vesicles through a series of filters under low 
pressure between 100-800 lb/in2, (where 1 lb/in2  = 6895 Pa) will  
be used in this project because it  allows for rapid and 
reproducible production of narrow, monodisperse vesicle 
populations with diameters close to the chosen pore size of the 
filter into liposomes (Mui and Hope 2007).  
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1.10 Various generations of liposomes  
 
The first generation of liposomes are conventional 
liposomes with “naked” phospholipid surfaces, without 
glycolipids, hydrophilic polymers or other surface grafted 
components (Allen and Stuart 1999). Initially liposomes were 
produced from unsaturated lipids such as egg 
phosphatidylcholine but these were found to be rapidly cleared 
from the bloodstream due to opsonization by plasma proteins and 
accumulation in the reticuloendothelial system (RES) 
(Scherphof, Dijkstra et al.  1985; Senior 1987).  The use of small 
liposomes (around 100 nm) containing saturated fatty acyl chains 
and cholesterol has extended blood circulation time (Kirby, 
Clarke et al.  1980; Senior and Gregoriadis 1982; Senior, Crawley 
et al .  1985) .  Currently, three of the four marketed products for 
cancer treatment, namely, Myocet (liposomal doxorubicin), 
Daunoxome (liposomal daunorubicin) and DepoCyt (liposomal 
cytarabine) belong to the first generation of liposomes.  
The second generation of liposomes consists of sterically 
stabilized liposomes where surface grafted hydrophilic polymers 
such as poly(ethylene glycol) are incorporated. The polymers 
reduce the recognition of the liposomes by the RES and hence, 
these liposomes have longer circulation half lives, which 
increases the levels of drug accumulation in the site of tumor 
growth as compared to the first generation liposomes 
(Papahadjopoulos, Allen et al.  1991). In addition, it  has been 
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found that sterically stabilized liposomes could also prevent 
liposome aggregation and fusion with biological membranes to 
increase circulation half life (Cattel, Ceruti  et  al.  2003). Doxil 
(liposomal doxorubicin) is an example of a second generation 
liposome preparation available in the market. The circulation 
half life of Doxil is three times (Gabizon, Catane et al.  1994) 
that of Myocet (Cowens, Creaven et al.  1993), a first generation 
liposomal doxorubicin preparation. 
The third generation of liposomes involves the attachment 
of ligands against cell  surface antigens expressed selectively on 
tumor cells on the liposomes so as to increase the therapeutic 
efficacy of drugs encapsulated in them. These include the folate 
receptor (Andrew and Philip 2005), transferrin receptor (Singh 
1999), antibodies (Sofou and Sgouros 2008) and peptides 
(Torchilin 2006). At the present moment, peptide-targeting with 
mucin 1 is being tested in Phase II clinical trials (Table 4).   
The fourth generation of liposomes is designed to release 
drug at the target site in response to external stimuli.  Currently, 
researchers have used external stimuli such as heat (Sandstroem, 
Ickenstein et al.  2005; Woo, Chiu et al.  2008), magnetism 
(Viroonchatapan, Sato et al.  1996; Kubo, Sugita et al.  2001; 
Dandamudi and Campbell 2007) and ultrasound (Huang 2010; 
Negishi,  Omata et al.  2010; Suzuki and Maruyama 2010; Suzuki, 
Namai et al.  2010). Of these approaches, the use of temperature 
is the most advanced, where thermosensitive doxorubicin 
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l iposomes are being tested in Phase I clinical trials 
(clinicaltrials.gov). This approach is suitable for locally 
occurring cancers that can be readily assessed by the application 
of external stimuli,  such as melanomas. 
Based on the developments in the field, future liposomal 
delivery systems will  become increasingly sophisticated and 
multifunctional l iposomes, such as liposomes with targeting and 
local release functions may be developed in the future as an 
armamentarium against cancer.  
 
1.11 Lipids used for liposome making 
 
1.11.1  Phospholipids 
 
Phospholipids provide the structural framework and a 
major component of the cell membrane. All phospholipid 
molecules have a polar head group, a phosphate group and 
hydrophobic fatty acid chains connected by a glycerol backbone 
(Figure 3). At physiological pH, the phosphate group of the 
phospholipid molecule is negatively charged. The negative 
charge can be neutralized by the presence of positively charged 
headgroups, such as choline or ethanolamine. In contrast,  when 
the headgroup is neutral,  as in the cases of phosphatidylserine, 
phosphatidylglycerol,  the phospholipid has an overall negative 
charge. Charged lipids can be used to reduce flocculation over 
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the shelf life of the product, influence drug retention and loading 
and direct liposomes to biological targets (Maurer-Spurej,  Wong 
et al .  1999; Tardi, Gallagher et  al.  2007). Besides alterations in 
the headgroup, alterations in acyl chain length can also affect 
stability, permeability and phase behavior of the liposomes 
(Anderson and Omri 2004). The most common acyl chain lengths 
used for drug delivery are myristic (C14), palmitic (C16) and 




Figure 3 Structure of Phosphatidylcholines. 
The most common phospholipids used in liposome making 
are the phosphatidylcholines (PC). PCs can be extracted from 
natural sources such as eggs, soy, brain and the liver. However, 
these natural extracts are a mixture of different lipids, including 
saturated and unsaturated PCs of different acyl chain lengths and 
sphingolipids and the lipid composition may vary from batch to 
batch. Besides natural sources, PCs can also be chemically 
synthesized. The advantage of chemically synthesized PCs is that 
they are chemically pure, and most current l iposome work 
involves the use of chemically synthesized lipids.  
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Sphingolipids are another class of phospholipids 
commonly used in liposome making. They also occur naturally 
and are important components of the brain and nerve tissue. 
Sphingolipids have a sphingosine backbone. This backbone has 
one more hydroxyl and one more amino group as compared to the 
glycerol backbone of the phosphatidylcholines (Figure 4). 
Sphingolipids can be incorporated to reduce the permeability of 
lipid membranes through the formation of hydrogen bonds 
(Torchilin and Weissig 2003). 
 
 
Figure 4 Structure of sphingomyelin. 
 
1.11.2 Poly(ethylene glycol) conjugated lipids 
 
Poly(ethylene glycol) (PEG) is a non-toxic, non-antigenic 
polymer that is commonly conjugated to phospholipids. 
Poly(ethylene glycol) conjugated lipids are incorporated into 
liposomes to impart steric stabilization and prolong in vivo  
circulation time of the liposomes (Woodle and Lasic 1992). The 
optimal molecular weight of PEG for prolonging the in vivo  
circulation time is 2,000 (de Gennes 1987; Woodle and Lasic 
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1992; Dos Santos, Allen et al.  2007). Due to the negative charge 
on the phosphate moiety, the poly(ethylene glycol) conjugated 
lipid is negatively charged when it  is conjugated to lipids with a 
neutral headgroup such as distearoylphosphatidylethanolamine 
(DSPE) (Figure 5). In most cases, DSPE-PEG200 0  is being used 
(Papahadjopoulos, Allen et al.  1991; Zamboni 2005) but the 
negative charge may increase drug leakage, necessitating the use 











Figure 6 Diagram of N-palmitoyl-sphingosine-1-
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In a phospholipid bilayer, the lipid anchor partitions 
within the lipid bilayer while the PEG moiety extends from the 
liposome surface (Papahadjopoulos, Allen et al.  1991). 
Depending on the grafting density of PEG lipids on the bilayer, 
the PEG component can form either “mushroom” (less than 5 
mol% of DSPE-PEG2 000),  “brush” conformation (between 5 to 10 
mol% of DSPE-PEG2 000).  Mixed micelles are formed when the 
PEG component exceeds 10 mol% (de Gennes 1987). These 
conformations are illustrated in Figure 7. In the “mushroom” 
conformation, PEG can move freely from a fixed point that 
encompasses a half-sphere which exhibits a defined radius called 
Flory radius (Rf).  This conformation occurs at low grafting 
densities (D>Rf), where polymer-polymer interactions are 
minimal. At high PEG concentrations (D<Rf),  polymer-polymer 
interactions occur and the PEG polymers extend out from the 
lipid bilayer (brush regime). These are illustrated on Figure 8. At 
even higher PEG concentrations, mixed micelles are formed to 
reduce the interactions between the PEG chains (Hristova and 
Needham 1994). Since poly(ethylene glycol) conjugated lipids 
are incorporated into liposomes to impart steric stabilization, the 
concentration of PEG lipids is usually between 5 – 10 mol%, 




 33   
 
 
Figure 7 Diagram illustrating the different structures that can be 









Figure 8 The conformation adopted by PEG is dependent on the 
grafting distance between the polymers (D) and the Flory radius 
(Rf) of the polymer.  
 
1.11.3  Cholesterol 
 
Cholesterol has a 4-membered sterol ring with a 
hydrocarbon chain and a hydrophilic hydroxyl group (Figure 9). 
Currently, most liposomal formulations contain a high 
percentage of cholesterol (around 50%) so as to confer biological 
stability in vivo  as cholesterol reduces interaction with plasma 
“Mushroom” 
regime:  
DSPE-PEG2 000  
<5 mol%  
“Brush” regime: 
DSPE-PEG2 000 :  
5-10 mol%  
Micelle formation: 









D >> Rf  
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proteins which destabilize the liposomes (Kirby, Clarke et al.  
1980; Senior and Gregoriadis 1982; Senior 1987; Gabizon, 
Catane et al.  1994). However, recent research has shown that the 
presence of DSPE-PEG20 00  could also reduce the interaction of 
liposomes with plasma proteins (Bartucci, Pantusa et al .  2002), 
hence cholesterol may not be needed to reduce plasma protein 
interaction in the presence of PEG-conjugated lipids.  
In addition, although it  was thought that the inclusion of 
cholesterol would enhance the retention of entrapped hydrophilic 
drugs in the liposome carrier (Demel and De Kruyff 1976), 
recent studies have shown otherwise. In fact,  the liposomal 
retention of some chemotherapeutic drugs was dramatically 
enhanced by the removal of cholesterol (Dos Santos, Waterhouse 
et al .  2005; Tardi, Gallagher et al .  2007). Lastly, cholesterol has 
an impact on the gel to liquid phase transition temperatures and 
this will  be discussed in Section  1.11.4.  
 
 
Figure 9  Structure of cholesterol. 
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1.11.4  Gel-to-liquid crystalline phase transition 
 
Lipids undergo a gel-to-liquid crystalline phase transition 
beyond a critical temperature, called the transition temperature 
(Tc) (de Kruyff,  Demel et al.  1972). This is the temperature 
needed to change the lipid from an ordered gel phase, where the 
hydrocarbon chains are fully extended and closely packed, to the 
disordered liquid crystalline phase, where the hydrocarbon 
chains are randomly oriented and fluid. A higher transition 
temperature is observed with an increased length of hydrocarbon 
chains, increasing degree of hydrocarbon saturation and a 
reduction in headgroup size.  
The effect of cholesterol on phase transition temperatures of 
lipids has been elucidated with differential  scanning calorimetery 
(DSC) (de Kruyff, Demel et al.  1972). In fluid membranes (above 
Tc),  cholesterol increases order and packing density in the lipid 
membrane. In gel membranes (below Tc),  cholesterol reduces 
order and packing density in the lipid membrane. At high 
cholesterol concentrations more than 30 mol%, the measured 
phase transition is eliminated, and hence, the membrane is in the 
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1.12 Methods of drug loading into liposomes 
 
1.12.1  Passive loading 
 
Both hydrophobic and hydrophilic drugs can be passively 
entrapped in the liposomes. Hydrophobic drugs can be efficiently 
incorporated with the lipid bilayers by mixing the drug with 
lipids dissolved in organic solvent,  with encapsulation 
efficiencies of close to 100% (Allen and Stuart 1999). In 
contrast,  passive loading of water soluble drugs during the 
hydration stage is usually inefficient (< 10%) (Mayer, Cullis et 
al.  1994; Torchilin and Weissig 2003).  
 
1.12.2  Remote loading with acidic liposome interior 
 
Remote loading of hydrophilic drugs can be applied when 
the drugs have protonation sites and exist in equilibrium between 
protonated and unprotonated states between pH values of around 
pH 4 and pH 9 (Mayer, Bally et al.  1986; Haran, Cohen et al.  
1993; Mayer, Cullis et al.  1994). In this technique, drugs are 
loaded into preformed liposomes. The drugs are first  incubated at 
neutral pH in the liposomes with an acidic interior. The 
uncharged form of the drug will diffuse down this concentration 
gradient into the liposomes. Under acidic conditions, the drug 
becomes protonated and trapped in the liposome as the charged 
form of the drug is membrane impermeable. The diffusion of the 
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neutral drug will continue as long as the pH gradient is 
maintained between the interior and exterior of the liposome or 
until  all  the drugs have been taken up.  (Mayer, Bally et al.  1986; 
Mayer, Cullis et al.  1994; Fenske and Cullis 2007). High 
encapsulation efficiencies of up to 100% can be attained with 
this method.  
 
1.12.3 Ionophore mediated generation of pH gradients via transmembrane 
ion gradients  
 
Another method of generating a pH gradient can be through 
the use of ionophores and ion gradients (Fenske, Wong et al.  
1998). Liposomes are formed by extrusion in either manganese, 
magnesium or potassium sulphate salts.  These liposomes are 
passed down a column equilibrated in a sucrose-containing 
buffer. The drug is subsequently added. For liposomes with 
potassium salts,  the ionophore nigericin is added. For the 
liposomes with either Mn2 + or Mg2 +, the ionophore A23187 and 
ethylenediaminetetraacetic acid (EDTA) are used. A23187 
couples the outward flow of a single divalent cation to the 
inward flow of a pair of protons, while EDTA is used as a 
chelating agent for manganese or magnesium as they are 
transported out of the vesicles. In both cases, ionophore-
mediated ion transport is electrically neutral and results in 
acidification of the vesicle interior, thereby creating a pH 
gradient that drives drug uptake.  
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1.13 Chapter Summary 
 
 This Chapter has provided background information 
on cancer, inadequacies of current treatment cancer regimens, 
highlighted the problems preventing clinical use of quercetin, 
pros and cons of drug delivery systems delivering quercetin and 
background information on liposome technology. The following 
Chapter will  focus on the hypothesis and objectives of the 
project.  
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C h a p t e r  2  
HYPOTHESIS AND OBJECTIVES  
2.1 Thesis rationale and hypothesis 
 
Metastatic breast cancer has high relapse rates, 
highlighting the need to develop new treatment modalities 
against them. Quercetin is a flavonoid which is active against 
breast cancer and synergizes with many chemotherapeutic agents 
in vitro ,  but i ts clinical use is l imited by its low water solubility. 
Since liposomes have been shown to (i) solubilize hydrophobic 
drugs, (ii) co-encapsulate multiple agents in the same liposome 
and (iii) release chemotherapeutic agents in a controlled and co-
ordinated manner, it  was hypothesized that an appropriately 
designed liposome system can efficiently solubilize quercetin 
and co-encapsulate it   with conventional amphipathic 
chemotherapeutic agents with co-ordinated drug release, thereby 
maintaining the most synergistic molar ratio of the two drugs in 
vitro and in vivo  so as to increase the therapeutic efficacy as 
compared to the free drug combination. This would represent a 
ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ٛ ᄀٛ …  뒄 
or breast cancer.   
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2.2 Objectives 
 
The objectives of this project are to develop a liposomal 
formulation to solubilize quercetin so as to facilitate intravenous 
administration of quercetin. Secondly, chemotherapeutic drugs 
that synergize with quercetin in breast cancer cells will be 
identified by in vitro  studies by the median-effect equation. 
Thirdly, the quercetin/drug combinations showing synergism will  
be co-encapsulated into liposomes. Finally, the co-encapsulated 
formulation will  be evaluated in vitro  and in vivo  and compared 
with the free drug combination.  
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C h a p t e r  3  
MATERIALS AND METHODS  
3.1 Materials 
 
All  lipids were obtained from Avanti Polar Lipids (USA). 
MDA-MB-231 cells were obtained from the American Type 
Culture Collection and JIMT-1 cells were obtained from 
Deutsche Sammlung von Mikroorganismen und Zellkulturen 
GmbH (Germany). 3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide (MTT), dimethyl sulfoxide 
(DMSO), chloroform were purchased from MP Biomedicals,  Inc 
(Singapore).  Balb/c mice were purchased from the Centre for 
Animal Resources, National University of Singapore (Singapore) 
while SCID mice were purchased from the Biological Resource 
Centre, Biopolis (Singapore).  All other materials were purchased 
from Sigma-Aldrich (USA). 
 
3.2 In vitro cytotoxicity studies  
  
In vitro cytotoxicity was assessed by the 3-(4,5-
diethylthiazoyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
colorimetric cytotoxicity assay (Mosmann 1983). MDA-MB-231 
or JIMT-1 human breast cancer cells were grown in DMEM/F-12 
media supplemented with 10% fetal bovine serum and seeded at 
4000 cells/well in 96-well cell  culture plates. They were 
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incubated at 37 oC with 5% CO2 for 24 h for cell  adherence to 
the cell  culture plates. Cells were subsequently treated with 
serial dilutions of either single drugs (quercetin, vincristine), or  
drug combinations (quercetin and vincristine at molar ratios of 
4:1, 2:1, 1:1 and 1:2) for 72 h. Subsequently, 50 µL of 1 mg/mL 
MTT reagent was added to each well.  This was incubated with 
the cells for 4 h and aspirated. 150 µL of dimethyl sulfoxide 
(DMSO) was added to each well and the 96-well plates were 
shaken for 20 minutes to solubilize the cells.  The plates were 
read on a microplate absorbance meter (Tecan SunriseT M, 
Männedorf, Switzerland,) set at  570 nm. Cell survival at the end 
of treatment was calculated from the optical density readings as 
a percentage of the control.  All assays were performed in 
triplicate.  
 
3.3 Median-effect analysis  
 
CalcuSyn® (United Kingdom), a software program based 
on the median-effect principle described by Chou and Talalay 
(Chou and Talalay 1977) was used for the drug combination 
interaction analysis. For studies on the combined effects of 
quercetin with vincristine, fixed ratios of quercetin and 
vincristine (4:1, 2:1, 1:1 and 1:2) were used. The Calcu-Syn® 
program determines if the combined agents act in an additive, 
synergistic or antagonistic manner by using the mean cell 
survival percentages from the MTT assay as a function of drug 
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concentrations to generate a combination index (CI) value, which 
has been defined as being synergistic (CI < 0.9), additive (CI = 
0.9-1.1) or antagonistic (CI > 1.1).  
 
3.4 Liposome preparation 
 
Liposomes were prepared by the thin film hydration 
method (Mayer, Tai et al.  1990). Briefly, the lipids were 
dissolved in chloroform while quercetin was dissolved in ethanol 
and mixed by vortexing.  The preparation was subsequently dried 
under a stream of nitrogen gas, and the resulting lipid film was 
placed under vacuum to remove organic solvent. The dried lipid 
films were hydrated with 300 mmol/L manganese sulfate (pH3.4) 
for 1 h at 60 oC. The resulting preparation was extruded 15 times 
at 60 oC through one stacked 0.1 µm pore size polycarbonate 
filter (Northern Lipids Inc., Vancouver, BC, Canada) with an 
extruder apparatus (Northern Lipids Inc.,  Vancouver, BC, 
Canada). The resulting mean diameter of the liposomes was 
determined by quasi-elastic light scattering (QELS) using the 
Zetasizer 3000HS operating at 633 nm and had diameters around 
130 nm.  
 
3.5 pH gradient loading of irinotecan and vincristine 
 
Irinotecan or vincristine (drug-to-lipid molar ratio of 
0.1:1) were actively loaded into the liposomes using an 
ionophore-mediated proton gradient (Fenske, Wong et al.  1998). 
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The divalent cation ionophore A23187 (0.5 µg per 1 mg lipid) 
was incorporated into the liposomal bilayer after incubation at 
37°C or 10°C above the phase transition temperature of the lipid 
for 10 minutes. Subsequently, the efficiency of irinotecan 
encapsulation by liposomes (drug-to-lipid molar ratio of 0.1:1) 
was determined at incubation temperatures of 37°C or 10°C 
above the phase transition temperature of the lipid as a function 
of time. Encapsulated drug was separated from free drug using a 
Sephadex G-50 mini spin column. Irinotecan was quantified by 
measuring its fluorescence intensity with at an excitation 
wavelength at 385 nm and emission wavelength at 535 nm 
following the solubilization of the liposomal formulation. 
Quercetin was quantified by measuring its absorbance at 376nm 
after solubilization of the liposomes (Goniotaki,  Hatziantoniou et 
al.  2004) in ethanol. Vincristine was quantified by measuring its 
absorbance at 297nm (Waterhouse, Madden et al.  2005) after 
solubilization of the liposomes in n-Octyl -D-glucopyranoside. 
 
3.6 Evaluation of quercetin stability 
 
The stability of encapsulated quercetin was compared with 
unencapsulated quercetin with the 2,2-diphenyl-1-picrylhydrazyl 
(DPPH•) assay, which is a stable free radical used to measure the 
stability of quercetin (Casagrande, Georgetti  et al.  2007). The 
free quercetin and liposomal formulations of quercetin were 
stored at 37 oC for 2 weeks. DPPH• was incubated with the 
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samples containing 1µg/ml of quercetin for 10 minutes and its 
absorbance determined at 517 nm (Dinis, Maderia et al.  1994).  
 
3.7 Drug release studies  
 
The drug release characteristics of this formulation were 
assessed by dialyzing (3500 molecular weight cut off,  Pierce, 
USA) the liposomes against 2 liters of 0.9% w/v sodium chloride 
for 72 hours at 37°C. At 4, 6, 24, 48 hours, 3 x 50 µL aliquots 
were removed from the dialyzer and analyzed for encapsulated 
quercetin, irinotecan or vincristine concentrations with the same 
methods outlined in the previous Section.   
 
3.8 Animal studies  
 
All the mice used were female and between 20-22 g. They 
were housed in micro-isolator cages and given free access to 
food and water. They were quarantined for 7 days before the 
study was initiated. The studies were conducted according to the 
procedures approved by the National University of Singapore 
Institutional Animal Care and Use Committee. 
 
3.9 Pharmacokinetic studies  
 
Both free drugs and drug loaded liposomes (2:1 molar ratio 
of vincristine: quercetin; corresponding to 1.33 mg/kg vincristine 
and 0.24 mg/kg of quercetin) were injected intravenously into the 
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lateral tail  vein of female Balb/c mice. At 10 minutes, 30 
minutes, 1 hours, 2 hours, 4 hours and 24 hours after intravenous 
drug administration, the animals were euthanized with carbon 
dioxide asphyxiation and the blood collected by cardiac puncture 
(4 mice per time point).  Blood samples were centrifuged for 10 
minutes at 1000 g to isolate the plasma and stored at -20 ºC until  
analysis of quercetin and vincristine concentrations by UPLC. 
The liver and spleen were snap frozen in liquid nitrogen and 
stored at -80 oC until  analysis.  
 
3.10 In vivo efficacy study 
 
Tumors were established in SCID mice by a single 
subcutaneous injection of 5 x 106  JIMT-1 cells in the upper back 
area. Tumor progression was monitored by caliper measurements 
of the tumors along the length and width thrice a week. Tumor 
volumes were calculated by the following formula: Tumor 
volume = (length x width2)/2. When the tumor size reached 200-
300 mm3, mice were randomized into 5 groups of 5 animals each. 
The mice were either treated with (i) sucrose HEPEs buffer 
(vehicle) control (ii) free quercetin (ii i) free vincristine (iv) 
quercetin and vincristine (v) liposomal quercetin and vincristine. 
The doses of vincristine administered was 1.33 mg/kg (2/3 of the 
maximum tolerated dose in SCID mice (Waterhouse, Madden et  
al.  2005) and quercetin administered was 0.24 mg/kg. At these 
values, the molar ratio of vincristine: quercetin was 2:1. Tumor 
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size and body weight of the mice was monitored thrice weekly 
until  day 60. Animals whose tumor size reached 1000 mm3, 
developed ulcerations, displayed a weight loss of more than 5% 
were euthanized.  
 
3.11 UPLC method development and analysis 
 
A Waters AcQuity Ultra Performance Liquid 
Chromatography (UPLC) system (USA) was used to quantify 
quercetin and vincristine for the pharmacokinetic study. A 
Waters AcQuity UPLC BEH C18 2.1 x 50 mm, 1.7 μM column 
protected by a guard column was used. The assay was performed 
at 25 ºC with 0.1% formic acid as weak solvent and acetonitrile 
with 0.1% formic acid as strong solvent .  The initial phase 
composition comprised of 75% 0.1% formic acid (weak solvent) 
and 25% acetonitrile with 0.1% formic acid (strong solvent) and 
the final phase comprised of 5% 0.1% formic acid and 95% 
acetonitrile with 0.1% formic acid at 3.8 min at a flow rate 0.5 
ml/min and the detection wavelength of quercetin was 376 nm 
and that of vincristine was 297 nm.  
The procedure for extraction of quercetin and vincristine 
from plasma and organs were modified from previously reported 
methods (Yang, Hsiu et al.  2005; Park, de Oca et al.  2009). 
Briefly, the organs were weighed and 0.1 g of the organ was 
homogenized in 2 volumes of 0.2 M sodium acetate buffer (pH5) 
in a Retsch Mixer Mill MM 200 (Germany).  Either 100 μL of 
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plasma or organ tissue homogenate was mixed with 50 μL of β-
glucuronidase, sulfatase and 25 μL of ascorbic acid and 
incubated at 37 ºC for 1 hour in a capped amber HPLC vial 
purged with nitrogen gas. The plasma or homogenate was 
acidified with 10 μL of 0.1 N HCl with apigenin as the internal 
standard and extracted four times with 100 μL of ethyl acetate. 
The ethyl acetate layer was collected and evaporated under 
nitrogen gas to dryness and reconstituted with acetonitrile with 
0.1% formic acid for UPLC analysis. 1 μl  of the supernatant was 
injected into the UPLC system. The concentration of quercetin 
and vincristine in the sample was determined by comparing the 
peak area ratios of the samples versus a calibration curve 
obtained by spiking known amounts of quercetin and vincristine 
into pooled mice plasma or the respective tissue organs. 
Pharmacokinetic analyses were performed using non-
compartmental analysis with WinNonlin software standard 




Statistical analysis was performed using the NCSS 2004 
statistical analysis software (USA). All experimental data were 
expressed as mean ± SEM. T-test,  one way ANOVA and the post 
hoc Tukey test were used. Kaplan-Meier survival curves were 
compared with the log-rank test.  P values of less than 0.05 were 
considered to be statistically significant. 
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C h a p t e r  4  
QUERCETIN INCORPORATION INTO LIPOSOMES 
4.1 Introduction 
 
         As highlighted in Section 1.7, quercetin has low water 
solubility with log P value of around 3, hampering its clinical 
use. Liposomal incorporation of quercetin could be a potential 
means to solubilize quercetin to facilitate its intravenous 
administration. Therefore, this Chapter aims to (1) determine the 
optimal conditions for quercetin incorporation in liposomes, (2) 
evaluate whether liposomal incorporation of quercetin would 
solubilize quercetin, (3) determine the in vitro  drug release 
profile of liposomal quercetin and (4) compare the in vitro 




4.2.1 Effect of cholesterol on quercetin incorporation 
  
Both quercetin and cholesterol intercalate between the 
phospholipids in biological membranes (Hendrich 2006). 
Therefore, the presence of cholesterol could influence the 
incorporation of quercetin. As a consequence, the effect of 
cholesterol on quercetin incorporation was investigated by 
varying the cholesterol content while keeping the drug:lipid 
(D:L) molar ratio constant at 5:95. Table 5 shows that the 
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presence of cholesterol reduced quercetin incorporation. The 
percentage of quercetin incorporation was 100.4%, 89.0%, 30.3% 
and 5.4%, with standard error of mean (SEM) values of 9.6%, 
8.5%, 6.7% and 1.3% in the presence of 0.0%, 10.0%, 20.0%, 
40.0% of cholesterol,  respectively. In addition, the extent of 
solubilization of quercetin was also determined by dividing the 
quercetin concentration in the liposomes with the concentration 
of quercetin in water (80 µM). As shown in  Table 5, all  
l iposomal formulations solubilized quercetin and the extent of 
solubilization was highest at 0.0 mol% cholesterol.  
 
Table 5 Effect of cholesterol on the percentage incorporation of 
quercetin, quercetin concentration and extent of solubilization in 
DPPC liposomes.  
 
  Cholesterol concentration (mol%) 
  0.0 10.0 20.0 40.0 












880.5    
(5.4) 
794.9    
(5.8) 
280.7    
(5.4) 
84.6     
(4.4) 
Extent of solubilization 11.0 9.9 3.5 1.1 
a  The concentration of quercetin in water is 80 µM. 
DPPC/quercetin/cholesterol molar ratios were 95:5:0, 85:5:10, 
75:5:20 and 55:5:40 and the D:L ratio was kept at  5:95. Results 
shown are the average values ± SEM obtained from three 
independent experiments.  
 
 
4.2.2 Effect of incorporation of 5 mol% of DSPE-PEG2000 on the 
incorporation of quercetin 
 
DSPE-PEG2 000 was added to the formulation of the 
liposomes to confer stability in the biological milieu and to 
prevent aggregation of liposomes during storage (Dos Santos, 
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Waterhouse et al.  2005). As shown in Table 6 ,  the incorporation 
of quercetin into the liposomes was similar for the formulations 
with and without 5 mol% of DSPE-PEG20 00.  Hence, the 
incorporation of 5 mol% of DSPE-PEG20 00 did not affect  
quercetin incorporation.  
 
Table 6 Comparison of the percentage incorporation of quercetin 
in DPPC liposomes with or without 5 mol% of DSPE-PEG200 0.   
 
  % of DSPE-PEG2 000 
  0.0 5.0 
% incorporation of 
quercetin (SEM) 100.4 (9.6) 100.7 (1.3) 
Quercetin 
Concentrationa (µM) 
(SEM) 880.5 (5.4) 883.1 (3.2) 
Extent of solubilization 11.0 
 
11.0 
a  The concentration of quercetin in water is 80 µM. 
DPPC/quercetin/DSPE-PEG200 0 molar ratios were 95:5:0 and 
90:5:5. All formulations were formulated at D:L ratio of 5:95. 
Results shown are the average values ± S.E.M obtained from 
three independent experiments. 
 
 
4.2.3 Influence of different lipids on quercetin incorporation 
  
Besides cholesterol, changes in the type of lipid used can 
also influence quercetin incorporation in the liposomal 
membrane. Firstly, the effect of headgroups on the quercetin 
incorporation was assessed by comparing quercetin incorporation 
in 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC) with 
egg sphingomyelin (ESM), both containing 16 carbons in the acyl 
chain, with ESM comprising one more hydroxyl and amino group 
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at the headgroup. There was no significant difference in terms of 
quercetin incorporation (p >0.05).   
Subsequently, the effect of varying acyl chain length of 
the lipids was assessed. Phosphocholines comprising of 14 
carbon atoms 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine 
(DMPC), 16 carbon atoms 1,2-Dipalmitoyl-sn-Glycero-3-
Phosphocholine (DPPC), and 18 carbon atoms 1,2-Distearoyl-sn-
Glycero-3-Phosphocholine (DSPC) were used.  
Table 7 shows  the effect of different lipids on quercetin 
incorporation. There was no significant difference in terms of 
quercetin incorporation among the DMPC, DPPC and ESM 
groups (p>0.05). However, there was statistical difference for  
the DSPC group (p < 0.05) as compared to the DMPC, DPPC and 
ESM groups. 
 
Table 7 Effect of different lipids on quercetin incorporation.  
 
  Type of lipid 
  DMPC DPPC DSPC ESM 











concentration a   
(µM) (SEM) 
900.6      
(8.4) 
880.5      
(5.4) 
152.4*      
(4.6) 
884.6       
(9.7) 
Extent of 
solubilization 11.3 11.0 1.91* 11.1 
a  The concentration of quercetin in water is 80 µM. 
For all  the formulations, the D:L ratio was fixed at 5:95. Results 
shown are the average values ± SEM obtained from three 
independent experiments.  
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4.2.4 Effect of pH on quercetin incorporation in liposomal membranes 
  
There are a number of drug loading methods which can be 
used to load chemotherapeutic drugs into the aqueous core of the 
liposomes. This involves hydration of the lipids at different pH 
values. For example, drug loading with citrate buffer involves 
hydration at pH 4 (Mayer, Tai et al.  1990), the use of manganese 
sulphate involves hydration at pH 3.4 (Messerer, Ramsay et al. 
2004), the use of magnesium sulphate involves hydration at pH 
5.2 (Zhigaltsev, Maurer et al.  2005) while the passive 
encapsulation of drugs involves a pH of 7.5. pH has been shown 
to influence the incorporation of flavonoids in lipid membranes 
(Movileanu, Neagoe et al .  2000). Hence, the effect of pH on the 
incorporation of quercetin was studied to select an appropriate 
drug loading condition for the loading of chemotherapeutic drugs 
in the subsequent Chapters. The lipid formulation tested 
comprised of DPPC/DSPE-PEG20 00/Quercetin (90:5:5 molar 
ratio). Figure 10 shows that at acidic pH, quercetin incorporation 
was around 100 % but at pH 7.5, quercetin incorporation 
declined to 47.0 %. There was no significant difference in terms 
of quercetin incorporation at acidic pHs (p>0.05). However, 
there was statistical difference at pH 7.5 (p < 0.05) as compared 
to the other groups. 
 

























Figure 10 Effect of pH on the incorporation of quercetin in 
DPPC/DSPE-PEG200 0/Quercetin (90:5:5 molar ratio) liposomes. 
Results shown are the average values ± S.E.M obtained from 
three independent experiments, * p<0.05. 
 
 
4.2.5 Physical stability of the liposomes  
  
The three lipids with the best incorporation of quercetin 
were selected for studies on the physical stability of liposomes. 
DMPC/DSPE-PEG200 0/Quercetin (90:5:5 molar ratio), 
DPPC/DSPE-PEG200 0/Quercetin (90:5:5 molar ratio) and 
ESM/DSPE-PEG2 000/Quercetin (90:5:5 molar ratio) l iposomes 
were sized at regular intervals to assess their diameters and 
polydispersities after storage at 4ºC for 16 weeks. There were no 
significant change in the either the diameters (Figure 11a) or 
polydispersity  (Figure 11b) of the liposomes, indicating physical 























































Figure 11 (a) Diameters and (b) polydispersities of DPPC/DSPE-
PEG20 00/Quercetin (■),  DMPC/DSPE-PEG2 000/Quercetin (▲) and 
ESM/DSPE-PEG2 000/Quercetin (♦) liposomes over 16 weeks after 
storage at 4ºC. The D:L ratio was kept at 5:95 for all  three 
liposomal formulations. Results shown are the average values ± 
S.E.M obtained from three independent experiments. 
 
 
4.2.6 In vitro release profile of quercetin 
 
Figure 12 shows the release profile of DPPC/DSPE-
PEG20 00/Quercetin (90:5:5 molar ratio), DMPC/DSPE-
PEG20 00/Quercetin (90:5:5 molar ratio), and ESM/DSPE-
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PEG20 00/Quercetin (90:5:5 molar ratio) liposomes over 72 hours 
at 37ºC. There was no significant difference in the drug release 
profile among the three liposomal formulations (p> 0.05).  
The quercetin release data were further analyzed by fitting 
the data to the three most common release kinetics patterns for 
drug delivery systems, including zero order, first order and 
square root of time release models.  The coefficients of 
determination (r2) for different models are shown in (Table 8). 
The best r2  values were obtained for the square root of time 
release model with a r2  values of 0.95 for DPPC/DSPE-
PEG20 00/Quercetin liposomes, 0.85 for DMPC/DSPE-
PEG20 00/Quercetin liposomes and 0.94 for ESM/DSPE-































Figure 12 Release profile of quercetin at 37 ºC from different 
formulations of liposomes. DPPC/DSPE-PEG200 0/Quercetin is 
represented by ■ ,  DMPC/DSPE-PEG2 000/Quercetin is represented 
by ▲  and ESM/DSPE-PEG2 000/Quercetin is represented by ♦ .  The 
D:L ratio was kept at  5:95 for all  three liposomal formulations. 
Results shown are the average values ± S.E.M obtained from 
three independent experiments. 
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Table 8 r2  values of zero order, first  order and square root of 




4.2.7 Stability studies with quercetin 
  
DPPH●  is  a stable free radical which can either accept an 
electron or hydrogen radical to form a stable, diamagnetic 
molecule. Due to the presence of the odd electron, it  has a strong 
absorption band at 517 nm. When the electron becomes paired, 
the absorption at 517 nm decreases proportionally with respect to 
the number of electrons taken up. This change in absorbance can 
be used to test the ability of molecules to act as hydrogen 
donors.  
Prior stability studies have established that the hydroxyl 
groups on quercetin are vulnerable to oxidation (Zenkevich, 
Eshchenko et al.  2007). When this occurs,  the hydrogen donating 
ability of quercetin to DPPH●  is reduced, leading to a reduced 
change in absorbance of DPPH● .  Hence, the stability of 
liposomal encapsulated quercetin was compared with that of 









liposomes 0.73 0.66 0.95 
DMPC/DSPE-
PEG20 00/Quercetin 
liposomes 0.84 0.81 0.85 
ESM/DSPE-
PEG20 00/Quercetin 
liposomes 0.84 0.79 0.94 
The D:L ratio was kept at 5:95 for all  three liposomal 
formulations. 
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quercetin in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
buffered saline (HBS) buffer. Figure 13  shows the percentage 
reduction in hydrogen donating ability of quercetin over 14 days. 
Among the four groups, ESM/DSPE-PEG2 000/Quercetin and 
DPPC/DSPE-PEG200 0/Quercetin liposomes displayed similar 
profiles in terms of percentage reduction in hydrogen donating 
activity. They also showed smaller percentages in the hydrogen 
donating activity as compared to the other groups, followed by 
DMPC/DSPE-PEG200 0/Quercetin liposomes. Un-encapsulated 
quercetin showed the greatest reduction in hydrogen donating 
ability of quercetin. 
 
Figure 13 Comparison of un-encapsulated quercetin (x), 
ESM/DSPE-PEG2 000/Quercetin (90:5:5 molar ratio) (◊),  
DPPC/DSPE-PEG200 0/Quercetin (90:5:5 molar ratio) (■) and 
DMPC/DSPE-PEG200 0/Quercetin (90:5:5 molar ratio) (Δ) as 
assessed by the percentage reduction in hydrogen donating 
ability of quercetin. Results shown are the average values ± 
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4.2.8 In vitro cytotoxicity studies of liposomal quercetin 
  
From  Section 4.2.7, ESM/DSPE-PEG2 000/Quercetin and 
DPPC/DSPE-PEG200 0/Quercetin showed smaller percentages in 
the reduction in hydrogen donating ability of quercetin as 
compared to other groups, indicating that they conferred superior 
protection against quercetin degradation. Therefore, the 
cytotoxicity of these two formulations was assessed in two 
representative breast cancer cell  l ines, MDA-MB-231 and JIMT-
1.  
Before initiating the study on liposomes containing 
quercetin, in vitro  cytotoxicity studies of the liposomes without 
quercetin were first conducted on MDA-MB-231 and JIMT-1 
cells to determine if the liposome carrier itself contributed to the 
cytotoxicity of the cells.  The concentration of lipid tested was 
matched to the amount of lipid used in the formulation. At the 
concentrations of lipids used, there was no effect on the cell  kill  






















































Figure 14 In vitro  cytotoxicity of the liposome carrier (a) 
DPPC/DSPE-PEG200 0 (b) ESM/DSPE-PEG20 00  in MDA-MB-231 
cells. Results shown are the average values ± S.E.M obtained 

























































Figure 15 In vitro  cytotoxicity of the liposome carrier (a) 
DPPC/DSPE-PEG200 0 (b) ESM/DSPE-PEG20 00  in JIMT-1 cells.  
Results shown are the average values ± S.E.M obtained from 
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Although quercetin has a solubili ty of 80 µM in water, the 
solubility of free quercetin can be increased to 250 µM in the 
presence of 10% fetal bovine serum in cell culture media through 
its binding to serum proteins (van der Woude, Gliszczynska-
Swiglo et al.  2003). Therefore, the highest concentration of free 
quercetin tested was 250 µM. Table 9  shows the median-effect 
concentrations (EC50)  and linear correlation coefficient (r)  values 
of free, un-encapsulated quercetin, DPPC/DSPE-
PEG20 00/Quercetin liposomes and ESM/DSPE-PEG2 000/Quercetin 
liposomes in both JIMT-1 and MDA-MB-231 breast cancer cell 
l ines. EC50 is an indication of the potency of the drug, while r 
value indicates the goodness of fit  for the data to the median-
effect equation used to calculate EC50. As shown in Table 9, the 
amount of quercetin needed to attain the EC50  was reduced 
approximately 10-fold for both liposomal formulations as 
compared to free quercetin in both breast cancer cell  lines.  
  
Table 9 In vitro  cytotoxicity of quercetin in free and liposomal 
form.  
 
 Free Quercetin DPPC/DSPE-
PEG20 00/  
Quercetin 
ESM/DSPE-
PEG20 00/  
Quercetin 
 EC5 0a/ 
µM 
r EC5 0a/ 
µM 
r EC5 0a/ 
µM 
r 
JIMT-1 105.4 0.92 7.2 0.93 8.6 0.96 
MDA-
MB-231 
109.2 0.93 6.2 0.95 7.5 0.94 
a EC50 values were derived from 8 points. 
Both ESM/DSPE-PEG2 000/Quercetin and DPPC/DSPE-
PEG20 00/Quercetin liposomes were in 90:5:5 molar ratios, n=3 
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4.3 Discussion 
 
This Chapter aims to determine the optimal conditions for 
quercetin incorporation in liposomes, evaluate the extent of 
quercetin solubilization, and determine the in vitro  drug release 
and cytotoxicity profiles so as to select the optimal formulation 
for co-encapsulation with chemotherapeutic agents in the 
subsequent Chapters. The first parameter assessed was the effect 
of cholesterol on quercetin incorporation. Table 5 shows that the 
presence of cholesterol reduced quercetin incorporation. Two 
possible reasons could lead to this finding. Firstly, cholesterol 
competes with quercetin for the same space in the lipid bilayer 
(Zhang, Anyarambhatla et al.  2005). Therefore, an increase in 
the mole fraction of cholesterol would reduce the space available 
for quercetin in the lipid bilayer. Secondly, cholesterol 
incorporation in liposomes reduces the flexibility of the 
hydrocarbon chains of the lipids (Demel and De Kruyff 1976), 
hampering quercetin penetration into the lipid bilayer. The 
results obtained here were similar to those obtained for 
paclitaxel,  another hydrophobic compound, where an increase in 
the cholesterol content in liposomes decreased the loading 
efficiency of paclitaxel (Zhang, Anyarambhatla et al.  2005). The 
extent of solubilization of quercetin after liposomal 
incorporation was also determined. All l iposomal formulations 
solubilized quercetin (Table 5). This could be due to the 
incorporation of quercetin into the liposomal bilayer (Goniotaki, 
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Hatziantoniou et al.  2004), protecting it  from unfavorable 
interactions with water.    
As mentioned in Section 1.11.3, cholesterol increases the 
biological stability of the liposomes by reducing the interaction 
of the liposomes with plasma proteins which destabilize them 
(Kirby, Clarke et al.  1980; Senior and Gregoriadis 1982; Senior 
1987; Gabizon, Catane et al.  1994). However, recent research has 
shown that this could also be accomplished by DSPE-PEG2 000 
(Bartucci, Pantusa et al.  2002). Therefore, after it  has been 
established that quercetin incorporation was the most optimal 
with 0% cholesterol, 5 mol% of DSPE-PEG2 000 was added to the 
formulation to stabilize the liposomes. There was no statistical 
difference in quercetin incorporation after adding 5 mol% of 
DSPE-PEG2 000.   
Besides DSPE-PEG20 00,  the type of lipid used for liposome 
making can also influence quercetin incorporation. There was no 
significant difference in terms of quercetin incorporation 
between DPPC and ESM (p>0.05), suggesting that the presence 
of additional hydroxyl and amino groups on ESM did not have a 
significant impact on the incorporation of quercetin. This could 
be attributed to quercetin interacting primarily with the acyl 
chain of the phospholipids rather than the headgroup (Goniotaki,  
Hatziantoniou et al.  2004). Subsequently, the effect of acyl chain 
length on quercetin incorporation was explored. Quercetin 
incorporation was lowest in liposomes with DSPC. This could be 
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due to the formation of a more rigid lipid bilayer by DSPC 
(Anderson and Omri 2004) as compared to DMPC and DPPC, 
which can limit quercetin incorporation in the liposomes. 
As shown in Figure 10, the incorporation of quercetin at 
acidic pH was close to 100%. This is because at acidic pHs, 
quercetin is neutral and completely soluble in lipids (Movileanu, 
Neagoe et al.  2000). Therefore, the incorporation of quercetin 
into the lipid bilayer is high due to the favorable interactions 
with both the acyl group and the headgroup of the phospholipid. 
In contrast,  at alkaline pH, the incorporation of quercetin 
decreased to 47%. This could be due to the deprotonation of the 
hydroxyl-pyrone of quercetin (Figure 1), which leads to the 
formation of a negatively charged molecule. The percentage 
incorporation of quercetin could be reduced since the 
intercalation of a charged quercetin molecule in the hydrophobic 
space between the phospholipids is less unfavorable. In 
summary, the incorporation of quercetin is close to 100% at 
acidic pH, the citrate, manganese and magnesium sulphate 
gradients can be used in the loading of chemotherapeutic drugs 
without adversely affecting the incorporation of quercetin.  
Subsequently, the size and polydispersity of the three 
formulations with the best quercetin incorporation, namely 
DMPC/DSPE-PEG200 0/Quercetin (90:5:5 molar ratio), 
DPPC/DSPE-PEG200 0/Quercetin (90:5:5 molar ratio) and 
ESM/DSPE-PEG2 000/Quercetin (90:5:5 molar ratio) were 
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monitored to assess their stability. In this Chapter, the size and 
stability of the liposomes were assessed for 16 weeks so that 
further studies on in vitro  drug release and cytotoxicity on the 
liposomes with good physical stability can proceed in a timely 
manner. A longer study period of 360 days will  be conducted for 
formulations that are chosen for co-encapsulation of 
conventional chemotherapeutic agents (Sections 6.2.5 and 7.2.6). 
Nevertheless, the absence of significant changes in either the 
diameters (Figure 11a) or polydispersity (Figure 11b) indicates 
physical stability, due to the presence of DSPE-PEG2 000,  
preventing aggregation after 16 weeks of storage (Dos Santos, 
Allen et al.  2007). 
After the stability studies, the three liposomal 
formulations were subjected to in vitro  quercetin release studies. 
The quercetin release data were further analyzed by fitting the 
data to the three most common release kinetics patterns for drug 
delivery systems. The best fit  was obtained for the square root of 
time release model for the three liposome formulations. This 
model suggests that quercetin incorporated in the liposome has to 
diffuse through the lipid bilayer to be released (Nounou, El-
Khordagui et al.  2006). The results obtained were consistent with 
that of another hydrophobic drug dibucaine, which was loaded in 
cholesterol free liposomes in a similar manner as quercetin. 
Dibucaine also had the best correlation for the square root of 
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t ime release as compared to the other models (Nounou, El-
Khordagui et al.  2006). 
Subsequently, the DPPH●  s tudy was used to assess the 
extent of quercetin degradation. All liposomal formulations 
showed less reduction in hydrogen donating activity of quercetin 
as compared to free quercetin.  This suggests that quercetin 
degradation was reduced in liposomal formulations, preserving 
the ability to reduce DPPH● .  However, the DMPC/DSPE-
PEG20 00/Quercetin formulation showed a greater percentage 
reduction in DPPH●  as compared to either ESM/DSPE-
PEG20 00/Quercetin or DPPC/DSPE-PEG20 00/Quercetin. This could 
be attributed to the quercetin molecule interacting primarily with 
the acyl chain of the phospholipids (Goniotaki, Hatziantoniou et  
al.  2004). Since DMPC has only 14 carbon atoms, and thereby a 
shorter acyl chain, hence it  conferred less protection from 
degradation compared with either ESM or DPPC, both with 16 
carbon atoms.   
Finally, the in vitro  cytotoxicity of quercetin liposomes 
was assessed in JIMT-1 and MDA-MB-231 breast cancer cells.  
The concentration needed to attain ED50  was reduced by 
approximately 10-fold in both cell  l ines after l iposomal 
incorporation, which can be explained by the results from the 
DPPH●  study. Encapsulated quercetin showed less reduction in 
the hydrogen donating activity compared with free quercetin 
(Figure 13). This could be due to the protective effect of 
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liposome incorporation, whereby the hydroxyl groups of 
quercetin are protected from oxidation which are necessary for 
the cytotoxicity of quercetin (Lopez-Lazaro 2002). It  should be 
highlighted that this effect was not reported in the previous work 
with EPC/Quercetin liposomes (Goniotaki,  Hatziantoniou et al .  
2004). This could be because saturated DPPC/DSPE-PEG2 000 
based liposomes are less likely to undergo lipid peroxidation 
(Ioku, Tsushida et al.  1995) compared to unsaturated egg 
phosphatidylcholine (EPC), where free radicals produced from 
lipid peroxidation could degrade quercetin to its less cytotoxic 
form (Lopez-Lazaro 2002).   
Overall,  the formulations of DPPC/DSPE-
PEG20 00/Quercetin (90:5:5 molar ratio) and ESM/DSPE-
PEG20 00/Quercetin (90:5:5 molar ratio) had high percentage 
incorporation of quercetin, good in vitro  stability, protected 
quercetin from degradation and improved the cytotoxcity of 
quercetin. Therefore, they will  be used in the subsequent 
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C h a p t e r  5  
EVALUATION OF VARIOUS COMBINATIONS OF QUERCETIN WITH 
CONVENTIONAL CHEMOTHERAPEUTIC AGENTS 
5.1 Introduction 
 
Cancer cells are heterogeneous as they acquire different 
genetic abnormalities (Hanahan and Weinberg 2000). Hence, the 
use of a single drug is unlikely to achieve significant cancer cell 
kill ,  and could even lead to the development of drug resistance 
due to insufficient cancer cell inhibition (Shah and Schwartz 
2001). Therefore, combination chemotherapy is the mainstay of 
cancer treatment (Devita, Serpick et al.  1970; Schwartz and 
Smith 1976; Keppen 2010). However, not all  drug combinations 
are beneficial.  Drugs may counteract each other, so that the 
treatment effect of combination is less than the sum activities of 
the individual agents (Drewinko, Loo et al.  1976; Abraham, 
McKenzie et al.  2004). In contrast,  when the drugs interact 
synergistically, the combined activities of the drugs are greater 
than that predicted from the contributions of the individual drugs 
(Paterson and Moriwaki 1969; Krainer 2003). Such synergism 
could produce equivalent efficacy at a fraction of doses of the 
individual drugs, thereby reducing dose-dependent side effects 
and improve patient response clinically (Shah and Schwartz 
2001). Therefore, there is a need to determine whether the 
combination is synergistic, antagonistic or additive before 
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clinical use. In this Chapter,  the synergy of quercetin with 
conventional chemotherapy drugs will  be analyzed with the Chou 
and Talalay median-effect principle through the CalcuSyn® 
software. 
As summarized in Section 1.6, quercetin exhibited 
synergism with camptothecin derivatives, plant alkaloids, 
alkylating agents and pyrimidine analogs in different types of 
human and animal cancer cell  l ines (Scambia, Ranelletti  et al.  
1990; Sliutz, Karlseder et al.  1996; Nakayama, Sakamoto et al.  
2000; Leslie, Mao et al.  2001; Akbas, Timur et al.  2005). In 
addition, irinotecan, vincristine, carboplatin and 5-fluorouracil 
have been shown to be effective against metastatic breast cancer 
refractory to first  l ine treatment (Ries and Dicato 1991; Chu, 
Sutton et al.  1996; Perez, Hillman et al.  2004; Chan, Yeo et al.  
2009). Hence, these drugs were selected and analyzed for 
synergy with quercetin in two representative breast cancer cell  
l ines, JIMT-1 and MDA-MB-231. These cell  lines were selected 
on the basis that they are hormone receptor negative and non 
responsive to trastuzumab treatment.  The aim of this Chapter is 
to determine whether irinotecan, vincristine, carboplatin and 5-
fluorouracil exhibit synergy with quercetin in the breast cancer 
cell  l ines, JIMT-1 and MDA-MB-231. 
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5.2 Results 
 
5.2.1 In vitro activities of quercetin, irinotecan, vincristine, carboplatin and 
5-fluorouracil monotherapy in JIMT-1 and MDA-MB-231 breast 
cancer cell lines  
 
JIMT-1 and MDA-MB-231 breast cancer cell l ines were 
treated with various concentrations of quercetin, irinotecan, 
vincristine, carboplatin and 5-fluorouracil monotherapy for 72 
hours. CalcuSyn® was used to determine the median-effect 
concentration (ED50) and linear correlation coefficient (r). The 
ED5 0 values indicate the potency of the drug while the r values 
show the goodness of fit  for the data to the median-effect 
equation used to calculate ED5 0. 
Table 10 EC5 0  and r values of quercetin, irinotecan, vincristine, 
carboplatin and 5-fluorouracil in JIMT-1 and MDA-MB-231 
breast cancer cells.   
 
 JIMT-1  MDA-MB-231  
 EC5 0a/ µM r EC5 0a/ µM r 
Quercetin  105.4 0.92 109.2 0.91 
Irinotecan  53.4 0.94 56.1 0.95 
Vincristine 15.9 0.98 8.4 0.94 
Carboplatin 118.4 0.90 92.4 0.96 
5-fluorouracil 142.1 0.95 98.3 0.98 
aEC50 values were derived from 8 points, n=3. 
 
 
5.2.2 Drug combination studies 
 
Drug combination studies designed to assess the 
concurrent administration of quercetin and (i) irinotecan, (i i)  
vincristine, (ii i)  carboplatin (iv) 5-fluorouracil were performed 
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and evaluated after 72 hours of drug exposure. Serial dilutions of 
irinotecan, vincristine, carboplatin and 5-fluorouracil were used 
while the concentrations of quercetin were fixed at the ED50  (100 
µM), ED20 (50 µM) and ED1 0 (25 µM) values of quercetin 
monotherapy. These levels of quercetin have been selected as 
they have been shown to have no significant effect on the growth 
of normal cells (Chowdhury, Kishino et al.  2005).  
Figure 16  and  Figure 17  i l lustrate the combination index 
(CI) values at different concentrations of quercetin and 
irinotecan for JIMT-1 and MDA-MB-231 breast cancer cells,  
respectively. The combination of quercetin and irinotecan was 
either synergistic or additive over a wide range of 
concentrations. For the two breast cancer cell  lines, the 
combination of irinotecan and quercetin showed either synergism 
or addition for concentrations below 250 µM and antagonism at 
the highest concentration tested at 500 µM.  
 
 

























Figure 16 Combination index values as a function of irinotecan 
concentration exposed to JIMT-1 breast cancer cells at  25 µM 
























Figure 17 Combination index values as a function of irinotecan 
concentration exposed to MDA-MB-231 breast cancer cells at  25 
µM (♦),  50 µM (■) and 100 µM (▲) of quercetin. 
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Figure 18  and  Figure 19  show the CI values plotted against 
concentration for quercetin and vincristine. For JIMT-1 and 
MDA-MB-231 cells,  combining either 25 µM or 50 µM of 
quercetin with varying concentrations of vincristine were found 
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Figure 18 Combination index values as a function of vincristine 
concentration exposed to JIMT-1 breast cancer cells at  25 µM 






















Figure 19 Combination index values as a function of vincristine 
concentration exposed to MDA-MB-231 breast cancer cells at  25 
µM (♦),  50 µM (■) and 100 µM (▲) of quercetin. 
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Figure 20  and  Figure 21  show the CI values at varying 
concentrations of carboplatin and quercetin for JIMT-1 and  
MDA-MB-231 breast cancer cells respectively. The best synergy 
was observed with the combination of carboplatin and 100 µM of 
quercetin while the other concentrations where either 
























Figure 20 Combination index values as a function of carboplatin 
concentration exposed to JIMT-1 breast cancer cells at  25 µM 























Figure 21 Combination index values as a function of carboplatin 
concentration exposed to MDA-MB-231 breast cancer cells at  25 
µM (♦),  50 µM (■) and 100 µM (▲) of quercetin. 
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Lastly,  Figure 22  and  Figure 23  show the CI values at 
varying concentrations of 5-fluorouracil and quercetin for JIMT-
1 and MDA-MB-231 cells,  respectively. In both cell l ines, 
synergistic or additive effect was observed at lower 
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Figure 22 Combination index values as a function of 5-
fluorouracil concentration exposed to JIMT-1 breast cancer cells 
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Figure 23 Combination index values as a function of 5-
fluorouracil concentration exposed to MDA-MB-231 breast 
cancer cells at  25 µM (♦),  50 µM (■) and 100 µM (▲) of 
quercetin. 




The anti-cancer activity of chemotherapeutic drugs is drug 
ratio dependent, exhibiting synergism at some ratios but 
additivity or antagonism at other ratios (Mayer, Harasym et al .  
2006; Harasym, Liboiron et al.  2009; Tardi,  Johnstone et al.  
2009). In order to screen for a wider range of drug ratios with a 
smaller number of experiments, the concentration of the 
chemotherapeutic agents were varied while the concentration of 
the quercetin was kept constant at 25 µM, 50 µM and 100 µM, 
which were selected as they have been shown to have no 
significant effect on the growth of normal cells (Chowdhury, 
Kishino et al.  2005). Table 10 shows that the r values of all  the 
drugs tested were above 0.90. Hence, the data had good 
conformity with the median-effect equation, and the EC50 values 
obtained reflect the potency of the drugs (Chou and Talalay 
1977). This in turn confirmed the reliability of the CI values, 
which were derived from the EC5 0 values (Chou 2008).  
In this Chapter,  combination studies of quercetin and 
irinotecan showed that there was synergy between these two 
drugs over a wide range of concentrations (Figure 16  and  Figure 
17).  The results are consistent with previous work by Akbas et 
al. ,  which had also demonstrated synergy between quercetin and 
camptothecin derivatives in the MDA-MB-231 breast cancer cell  
l ine through the inhibition of tyrosine specific protein kinase by 
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quercetin (Akbas, Timur et al .  2005). Another possible 
mechanism for synergy could be the effect of quercetin on heat 
shock proteins, a protein which confers resistance of cancer cells 
to certain anti-cancer drugs. Quercetin downregulated Hsp70 
expression in fibrosarcoma WEHI-S cells and reduced the 
concentration of camptothecin derivatives needed to exert 
cytotoxic activity (Sliutz, Karlseder et al.  1996), which could 
also be a possible mechanism leading to synergy between 
quercetin and irinotecan in the breast cancer cell  lines.  
As shown in  Figure 18 and  Figure 19 ,  quercetin and 
vincristine displayed synergy over a wide range of 
concentrations in breast cancer cells. A possible mechanism 
could be extrapolated from LY294002 (Figure 24), which was 
developed based on quercetin as the lead compound (Vlahos, 
Matter et al.  1994). LY294002 has been shown to enhance the 
induction of apoptosis by vincristine through the activation of 
glycogen synthase kinase-3β ,  which phosphorylates microtubule-
associated protein tau (MAPT) and thereby reduces their ability 
to bind and stabilize microtubules. This increased the sensitivity 
of cancer cells to vincristine, especially at low concentrations of 
vincristine that alone do not lead to the disruption of cytoplasmic 
microtubules (Fujiwara, Hosokawa et al.  2007). Given the 
structural similarities between quercetin and LY294002, the 
synergism with vincristine could be due to similar pathways as 
well.   
 79   
 
Figure 24 Structure of LY294002. 
 
For carboplatin, antagonism was observed at low quercetin 
concentrations and synergism at high concentrations across al l  
the cell  l ines (Figure 20 and Figure 21). This could be due to the 
dependency of alkylating agents such as carboplatin on the 
generation of reactive oxygen species for its cytotoxicity 
(Godbout, Pesavento et al.  2002). At quercetin concentrations 
less than 100 µM, quercetin acts as an antioxidant (Lee, Kim et  
al.  2003), thereby antagonizing the effects of carboplatin. In 
contrast,  at  higher concentrations of 100 µM, quercetin acts as a 
prooxidant (Laughton, Halliwell et al.  1989), synergizing with 
carboplatin in cancer cell kill .   
Finally, antagonism was observed for 5-fluorouracil and 
quercetin at most of the concentrations tested in all cell lines 
(Figure 22  and  Figure 23). This could be attributed to quercetin 
arresting cancer cells in the late G1 phase of the cell  cycle 
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(Yoshida, Yamamoto et  al.  1992), thereby preventing the cells 
from entering the S phase in which 5-fluorouracil  acts. 
Taking the data together,  the combinations of quercetin 
with either irinotecan or vincristine were more synergistic as 
compared to that of carboplatin and 5-fluorouracil.  Based on the 
results obtained, the co-enencapsulation of quercetin with (i) 
irinotecan and (ii) vincristine in liposomes will be attempted in 
the subsequent Chapters.  
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C h a p t e r  6  
CO-ENCAPSULATION OF QUERCETIN AND IRINOTECAN 
INTO LIPOSOMES 
 
6.1 Introduction  
 
In Chapter 5, quercetin was shown to synergize with 
irinotecan in breast cancer cell l ines over a wide range of 
concentrations. Irinotecan is a water-soluble analogue of 
camptothecin which acts during the S-phase of DNA replication 
by stabilizing the complex formed between topoisomerase I and 
DNA (Kawato, Aonuma et al.  1991). It  is active against ovarian, 
colorectal and small-cell  cancer lung cancers (Rosen 1998). In 
addition, irinotecan is currently undergoing clinical trials for 
metastatic breast cancer refractory to anthracyclines, taxanes or 
both (Perez, Hillman et al.  2004). Despite its promising anti-
cancer activity, irinotecan is hydrolyzed from the active lactone 
to the inactive carboxylate form at physiological pH (Chollet,  
Goumaz et al.  1998). This is illustrated on Figure 25. Therefore, 
encapsulation of irinotecan in a drug carrier can protect 
irinotecan from hydrolysis to its inactive carboxyl group, thereby 
increasing therapeutic efficacy. 
Irinotecan has been entrapped in DSPC/Cholesterol (55:45 
mol%) liposomes with an Mn2 +/A23187-mediated proton 
gradient. The A23187 ionophore generates a stable 
transmembrane gradient by transferring two protons for each  

















Figure 25 Inactivation of irinotecan under basic conditions.  
 
Mn2 + ion transported out from the inner core of the liposomes for 
protons in the external buffer (Fenske, Wong et al.  1998). This 
creates an acidic inner core which can maintain irinotecan in its 
active lactone form. In addition, this formulation has been shown 
to increase the circulation longevity of irinotecan as compared 
with free irinotecan and has also been shown to be more 
effective in the treatment of two models of colorectal cancer 
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However, in Chapter 4  i t  was found that  the presence of 
cholesterol and DSPC led to low quercetin incorporation. In 
contrast, the liposomal formulation of DPPC/DSPE-
PEG20 00/Quercetin (90:5:5 molar ratio) showed 100% quercetin 
incorporation. In addition, due to the structural similarilty of 
DPPC and DSPC, which had been previously used to load 
irinotecan, this formulation was selected instead of the 
ESM/DSPE-PEG2 000/Quercetin (90:5:5 molar ratio).  Therefore, 
irinotecan will  be loaded into DPPC/DSPE-PEG2 000/Quercetin 
(90:5:5 molar ratio) liposomes with the Mn2 +/A23187-mediated 
proton gradient.  Despite the advantages of irinotecan 
encapsulation in liposomes, irinotecan loading in cholesterol free 
liposomes has not been attempted previously. Therefore, the 
objectives of this Chapter are to (1) determine the optimal molar 
ratio to co-encapsulate irinotecan and quercetin, (2) develop a 
physically stable liposomal formulation that can co-encapsulate 
quercetin and irinotecan efficiently, (3) determine the release 
profile of quercetin and irinotecan and (4) evaluate the in vitro  




6.2.1 In vitro activities of quercetin and irinotecan 
 
Recently, it  was found that the efficacy of 
chemotherapeutic drugs can be enhanced by administering them 
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in their synergistic ratio (Mayer, Harasym et al.  2006). In 
Chapter 5, a wide range of ratios of quercetin and 
chemotherapeutic drug were tested by fixing the concentration of 
quercetin at 25 μM, 50 μM and 100 μM while changing the 
concentration of the chemotherapeutic drug. Irinotecan and 
quercetin were found to synergize over wide concentration 
ranges. Therefore, in this Section, the optimal molar ratio to 
encapsulate quercetin and irinotecan in the liposomes was 
assessed from the combination index values at the fixed 
irinotecan/quercetin molar ratios of 4:1, 2:1, 1:1, and 1:2 in two 
representative breast cancer cell  l ines MDA-MB-231 and JIMT-
1. These ratios were selected based on the expectation that the 
two drugs could be successfully encapsulated in liposomes. The 
optimal ratio will  be used for liposome encapsulation.  
Figure 26 shows the CI values at the four molar ratios of 
quercetin/irinotecan at ED75,  the dose needed to attain 75% cell  
kill .  CI values at ED7 5  are shown because the aim of cancer 
treatment is to eradicate cancer cells, hence high cell kill  values 
are more clinically relevant as compared to low cell kill  values 
(Harasym, Tardi et al.  2007). The CI values of 
irinotecan/quercetin at molar ratios of 4:1, 2:1, 1:1 and 1:2 were 
0.189, 0.0180, 0.0252 and 0.0408  for JIMT-1 cells and 0.0409, 
0.0125, 0.0147 and 0.0499  for MDA-MB-231 cells.   Therefore, 
the most optimal irinotecan/quercetin molar ratio was 2:1. Since 
the quercetin/lipid molar ratio was 0.05, the irinotecan/lipid 
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molar ratio to be encapsulated will be 0.1, so as to achieve the 
2:1 irinotecan/quercetin drug molar ratios.  
 
4:1 2:1 1:1 1:2























Figure 26 Combination index (CI) values at ED75 for 
irinotecan/quercetin exposed to JIMT-1 (white bars) and MDA-
MB-231 (black bars) breast cancer cells at molar ratios of 
irinotecan/quercetin of 4:1, 2:1, 1:1 and 1:2. Each value 
represents the mean ± SEM from three independent experiments.  
CI values of 0.9-1.1 indicate additive activity, CI values < 0.9 
indicate drug synergy and values > 1.1 indicate antagonism. 
 
6.2.2 Effect of ionophore on irinotecan loading 
 
Firstly, the role of ionophore A23187 in irinotecan loading 
into cholesterol free liposomes was determined. Figure 27 shows 
that a maximum of 27.3 % of irinotecan could be loaded at 55 ºC 
in the absence of ionophore; whilst a maximum of 15.0 % 
irinotecan could be loaded at 37 ºC (Figure 28) .  This percentage 
of drug loading was similar with cholesterol containing 
liposomes (Fenske, Wong et al.  1998).  































Figure 27 Irinotecan loading into DPPC/DSPE-PEG2 000/Quercetin 
liposomes (90:5:5 molar ratio) in the absence (∆) and presence of 
ionophore (■) at 55 ºC. Results shown are the average values ± 































Figure 28 Irinotecan loading into DPPC/DSPE-PEG2 000/Quercetin 
liposomes (90:5:5 molar ratio) in the absence (∆) and presence of 
ionophore (■) at 37 ºC. Results shown are the average values ± 







* * * *
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6.2.3 Effect of quercetin incorporation on irinotecan loading 
 
Since quercetin is incorporated in the lipid bilayer 
(Goniotaki,  Hatziantoniou et al.  2004), the presence of quercetin 
could influence the permeability of the liposomes, thereby 
affecting irinotecan loading. Hence, the effect of quercetin 
incorporation on irinotecan loading with the Mn2+/A23187-
mediated proton gradient was explored at 37 ºC and 55 ºC. As 
shown in Figure 29 and Figure 30 ,  there was no statistical 







































Figure 29 Comparison of irinotecan loading in DPPC liposomes 
in the presence and absence of quercetin at 55 ºC in the presence 
of ionophore. DPPC/DSPE-PEG2 000 (95:5 molar ratio) liposomes 
are represented by (∆) and DPPC/DSPE-PEG2 000/Quercetin 
(90:5:5 molar ratio) liposomes are represented by (■).  Results 
shown are the average values ± SEM obtained from three 
































Figure 30 Comparison of irinotecan loading in DPPC liposomes 
in the presence and absence of quercetin at 37 ºC. DPPC/DSPE-
PEG20 00 (95:5 molar ratio) liposomes are represented by (∆) and 
DPPC/DSPE-PEG200 0/Quercetin (90:5:5 molar ratio) liposomes 
are represented by (■).  Results shown are the average values ± 
SEM obtained from three independent experiments. * p<0.05. 
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6.2.4 Effect of temperature on the loading of irinotecan into DPPC/DSPE-
PEG2000/Quercetin (90:5:5 molar ratio) liposomes  
 
After determining the role of quercetin on irinotecan 
loading, the role of temperature on irinotecan loading with the 
Mn2 +/A23187-mediated proton gradient was assessed. As shown 
in Figure 31, 75.5% of irinotecan was loaded by 10 minutes and 
the maximal loading efficiency of irinotecan was 83.7% at 55 ºC. 
In contrast,  only 9.8% of irinotecan was loaded by 10 minutes 
and the maximum percentage of irinotecan loaded was 55.3 % at 
37 ºC. Hence, irinotecan loading was faster and more efficient at 
55 ºC compared with 37 ºC. Quercetin levels were reassessed 
after irinotecan loading and was shown to be similar to the levels 






























Figure 31 Effect of temperature on irinotecan loading in 
DPPC/DSPE-PEG200 0/Quercetin (90:5:5 molar ratio) liposomes at 
37 ºC  (∆)  and 55 ºC (■).Results shown are the average values ± 




* * * *
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6.2.5 Physical stability of the liposomes  
 
Size and polydispersity of the DPPC/DSPE-
PEG2000/Quercetin liposomes loaded with irinotecan were 
studied for 360 days at the storage temperature of 4 ºC. As 
shown in  Figure 32  and Figure 33 ,  there was no significant 
change in size and polydispersity over the entire monitoring 


























Figure 32 Diameters of DPPC/DSPE-PEG2 000/Quercetin 
liposomes (90:5:5 molar ratio) over 360 days. Results shown are 
the average values ± SEM obtained from three independent 
experiments. 
 






















Figure 33 Polydispersities of DPPC/DSPE-PEG2 000/Quercetin 
liposomes (90:5:5 molar ratio) over 360 days. Results shown are 
the average values ± SEM obtained from three independent 
experiments. 
 
6.2.6 In vitro drug release of irinotecan 
 
From Section 4.2.2 ,  the  incorporation efficiency of 
quercetin in DPPC/DSPE-PEG2 000/Quercetin (90:5:5 molar ratio) 
liposomes was 100.7% at 0.05 drug-to-lipid molar ratio and from 
Section 6.2.4, the irinotecan loading efficiency was 83.7% at 0.1 
drug-to-lipid molar ratio in DPPC/DSPE-PEG2 000/Quercetin 
liposomes. Hence the ratio of irinotecan/quercetin ratio in 
liposomes is 1.7. This value was obtained by (83.7 x 
0.1)/(100.7/100*0.05). This is close to the initial 
irinotecan/quercetin ratio of 2 and the co-encapsulated liposomes 
will  be used for in vitro  drug release studies (Section 6.2.6) and 
in vitro  cytotoxicity studies (Section 6.2.7). 
The in vitro release profile of irinotecan and quercetin 
from DPPC/DSPE-PEG2 000/Quercetin liposomes was assessed by 
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dialysis at 37ºC, and the results are shown in Figure 34 and 
Figure 35. The release profiles of the two drugs were unaffected 
by the presence of the other (p> 0.05). The release data were 
further analyzed by fitting into the three most common release 
kinetics patterns for drug delivery systems. They are zero order, 
first order and square root of time release models (Table 11 and 
Table 12).  The best coefficient of determination (r2) were 
obtained for the square root of t ime release model with r2  values 
of 0.98 for quercetin release in liposomes co-encapsulating 
quercetin and irinotecan, 0.95 for quercetin release in liposomes 
containing quercetin only, 0.97 for irinotecan release in 
liposomes containing quercetin and irinotecan and 0.96 for 
irinotecan release in liposomes without quercetin.  
Figure 36  shows the molar ratio of irinotecan and 
quercetin over the duration of the release study. There was no 
statistical difference in the molar ratios of irinotecan/quercetin 
for the first  48 hours as compared to the initial ratio, however, 
the molar ratio of irinotecan/quercetin was statistically different 



































Figure 34 In vitro  release profile of quercetin from liposomes 
loaded with quercetin only (∆) and loaded with both irinotecan 
and quercetin (■) at  37°C in 0.9%w/v sodium chloride 
determined with dialysis membrane. The liposome composition 
consisted of DPPC/Quercetin/DSPE-PEG2 000 (90:5:5 molar ratio).  































Figure 35 In vitro  release profile of irinotecan from liposomes 
loaded with irinotecan only (∆) and loaded with both irinotecan 
and quercetin (■) at  37°C in 0.9%w/v sodium chloride 
determined with dialysis membrane. The liposome composition 
consisted of DPPC/Quercetin/DSPE-PEG2 000 (90:5:5 molar ratio).  
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Table 11 r2  values of zero order, first  order and square root of 




Table 12 r2  values of zero order, first  order and square root of 

















Figure 36 Ratio of irinotecan/quercetin released over 72h. The 
ratios were obtained by dividing the drug:lipid ratios of 
irinotecan by that of quercetin. The dotted line represents the 
initial ratio of irinotecan/quercetin in the liposomes (1.7). Each 
value represents the mean ± SEM from three independent 
experiments, * p<0.05, one way ANOVA with post hoc Tukey 
test. 
 





of time drug 
release 
No irinotecana 0.80 0.94 0.95 
Irinotecanb 0.88 0.74 0.98 
aDPPC/DSPE-PEG200 0/Quercetin 90:5:5 molar ratio liposomes 
bDPPC/DSPE-PEG200 0/Quercetin 90:5:5 molar ratio liposomes co-
encapsulated with irinotecan 





of time drug 
release 
No quercetina 0.95 0.82 0.96 
Quercetinb 0.96 0.80 0.97 
aDPPC/DSPE-PEG200 0 95:5 molar ratio liposomes encapsulated 
with irinotecan 
bDPPC/DSPE-PEG200 0/Quercetin 90:5:5 molar ratio liposomes co-
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6.2.7 In vitro cytotoxicity studies on the liposomal formulation 
 
As mentioned in Section 4.2.8, empty liposomes 
comprising of DPPC/DSPE-PEG2 000 (95:5) molar ratio had no 
significant effect on cell viability in MDA-MB-231 and JIMT-1 
cells.  Liposomes encapsulating quercetin or irinotecan alone or 
the drug combination were diluted serially and exposed to both 
JIMT-1 and MDA-MB-231 breast cancer cell l ines for 72 hours. 
When irinotecan and quercetin were co-encapsulated, the 
concentrations of the two drugs required to attain 75% cell kill  
were reduced by approximately  one log-fold as compared to 
monotherapy in JIMT-1 cells (Figure 37). In addition, the CI was 
0.72 (synergistic)  at ED75. For the MDA-MB-231 cell l ine, the 
concentrations of irinotecan and quercetin required to attain 75% 
cell kill  were reduced by approximately 2 log-fold as compared 
to monotherapy for quercetin and 1 log-fold for irinotecan 
(Figure 38). In addition, the CI was 0.49  (synergistic) at ED7 5. 
Similar trends were observed at  other ED values in both cell 
l ines in terms of CIs. As explained in Section 6.2.7, ED7 5  values 
were reported here due to the clinical relevance of these values 
as compared to other ED values (Harasym, Tardi et al.  2007). 
 












































Figure 37 Plot of quercetin and irinotecan concentrations needed 
to achieve 75% cell kill  in JIMT-1 cells after liposomal 
encapsulation. Data were obtained with the CalcuSyn® software 
which uses the median dose effect method developed by Chou 
and Talalay to determine the Combination index. Each value 

















































Figure 38 Plot of quercetin and irinotecan concentrations needed 
to achieve 75% cell kill  in MDA-MB-231 cells after liposomal 
encapsulation. Data were obtained with the CalcuSyn® software 
which uses the median dose effect method developed by Chou 
and Talalay to determine the Combination index. Each value 
represents the mean ± SEM from three independent experiments.  
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6.3 Discussion 
 
Although synergy between quercetin and irinotecan had 
been reported previously (highlighted in Section 1.6), this is the 
first known attempt to co-deliver quercetin and irinotecan in a 
single drug carrier.  Besides being a novel combination in a drug 
carrier,  this is also the first  known attempt to load irinotecan in 
cholesterol free liposomes. Previous attempts by other groups to 
load irinotecan into liposomes used 45 mol% of cholesterol 
(Chou, Chen et al.  2003; Messerer, Ramsay et al .  2004; 
Drummond, Noble et al.  2006; Ramsay, Anantha et al.  2008). The 
drug loading efficiency and time needed for loading of irinotecan 
in DPPC/DSPE-PEG2 000/Quercetin liposomes was not 
significantly different from DSPC/Cholesterol l iposomes. Hence, 
drug loading rate was not adversely affected by the absence of 
cholesterol or the substitution of cholesterol with DSPE-PEG-
2 000.   
In addition, this is also the first  successful attempt in the 
use of temperatures above the phase transition temperature (Tc) 
of the lipid for drug loading in cholesterol free liposomes. 
Previously, drug loading into cholesterol free liposomes have 
been limited to the use of temperatures below Tc .  This was 
attributed to the collapse of the pH gradient at  temperatures 
above Tc ,  as cholesterol-free liposomes were more permeable 
above Tc  as compared to cholesterol containing liposomes (Dos 
Santos, Waterhouse et al.  2005). This had limited the utility of 
 98   
cholesterol free liposomes due to the longer drug loading times 
and lower drug:lipid ratio achievable as compared to 
conventional cholesterol containing liposomes. The ability to 
load drugs at temperatures above Tc in this Chapter could be 
attributed to the presence of ionophore A23187, which maintains 
a stable transmembrane gradient through proton exchange 
between the interior and exterior of the liposomes (Fenske, Wong 
et al.  1998) to prevent the collapse of pH gradient crucial to drug 
loading. 
The importance of the ionophore A23187 in irinotecan 
loading was further exemplified by  Figure 27  and  Figure 28.   In 
the absence of the ionophore, loading efficiency of irinotecan 
was only 27.3% as compared to 83.7% in the presence of the 
ionophore at 55 ºC. Similarly at 37 ºC, the loading efficiency of 
irinotecan was also lower in the absence of the ionophore (15.0 
%) versus 55.3% in the presence of ionophore. Some irinotecan 
could still  be loaded at both temperatures because the manganese 
sulphate solutions in the inner core of the liposomes are acidic 
(pH 3.4), generating a pH gradient with the buffer surrounding 
the liposomes (pH 7.5). In addition, irinotecan can also partition 
into the lipid bilayer and could contribute to irinotecan loading 
(Burke, Mishra et al.  1993). Nevertheless,  the low percentage of 
drug that could be loaded into the liposomes suggests that an 
ionophore is crucial in maintaining the transmembrane pH 
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gradient for higher drug loading in the Mn2 +/A23187-mediated 
proton gradient.   
The effect of temperature on the loading efficiency of 
irinotecan was also explored. The higher loading efficiency of 
irinotecan at 55 ºC as compared to 37 ºC could be explained as 
follows: At 55 ºC (14 ºC above the phase transition temperature 
of DPPC), the lipids are fluid,  facilitating the diffusion of 
irinotecan from the external buffer to the inner acidic aqueous 
core of the liposome. Once it  is in the aqueous core, irinotecan 
becomes charged due to the low pH and is subsequently trapped 
as charged molecules cannot diffuse through the membrane. In 
contrast,  below the phase transition temperature,at 37 ºC, the 
hydrocarbon chains of the lipids remain fully extended and 
closely packed. This configuration does not facilitate the 
diffusion of irinotecan through the membrane, leading to less 
efficient and slower irinotecan loading.  
In addition, when the size and polydispersity of 
DPPC/Quercetin/DSPE-PEG200 0 (90:5:5 molar ratio) liposomes 
was assessed over 360 days, there was no significant change in 
the size or polydispersity over the entire monitoring period, 
indicating the physical stability of the liposomes. This could be 
attributed to the sufficient steric hindrance conferred by 5 mol% 
of DSPE-PEG20 00, preventing the self aggregation of liposomes 
(Woodle and Lasic 1992). 
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Due to the different loading efficiencies of quercetin and 
irinotecan, the final irinotecan/quercetin ratio was 1.7, which is 
slightly different from the initial irinotecan/quercetin ratio of 2. 
However Figure 26 shows that significant synergism has been 
observed at the irinotecan/quercetin molar ratios of 2:1 and 1:1 
in both the JIMT-1 and MDA-MB-231 breast cancer cell l ines, 
this molar ratio is expected to be synergistic as well.  In vitro 
release studies showed that the ratio of irinotecan/quercetin was 
maintained close to the initial  irinotecan/quercetin ratio of 1.7 in 
the initial 48 hours, suggesting that the release of irinotecan and 
quercetin were co-ordinated; however by 72 hours the ratio of 
irinotecan/quercetin shifted to around 3. From the CI data in 
Figure 26 ,  which show that the irinotecan/quercetin molar ratios 
of 4:1 and 2:1 were synergistic, so a molar ratio of 3:1 is likely 
to be synergistic too. 
 The release data indicates that the release of the two 
drugs were unaffected by the presence of the other (Figure 34 
and Figure 35). Previous research has indicated that quercetin 
rigidifies lipid membranes through the formation of 
intermolecular hydrogen bonds (Tsuchiya, Nagayama et al.  
2002). This could alter the drug release profile from the 
liposomes. However, this effect did not occur here due to the 
lack of hydrogen bonding of quercetin with DPPC lipids 
(Pawlikowska-Pawlega, Ignacy Gruszecki et al .  2007). In 
addition, the release data was fitted into the common models of 
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drug release, and the data conformed to the square root of time 
release model best. Hence, both quercetin and irinotecan had to 
diffuse through the lipid bilayer of the liposomes in order to be 
released (Nounou, El-Khordagui et al.  2006). This could be due 
to the lipid composition of liposomes. The data demonstrated 
that the liposomes co-ordinated and controlled the release of 
quercetin and irinotecan.  
Finally, the liposomal formulation was tested on JIMT-1 
and MDA-MB-231 breast cancer cells.  The formulation displayed 
synergism in both cell  l ines (Section 6.2.7).  Figure 37  and  Figure 
38 show that both irinotecan and quercetin levels were reduced 
when used in combination hence, both drugs enhanced the cell 
killing effect of one another and this observation was not simply 
a “one sided” enhancement of cell  kill  by one agent (Chou 2008). 
In summary, a physically stable liposomal formulation that 
encapsulated both irinotecan and quercetin efficiently and co-
ordinated their release over 48 hours has been developed. The 
liposomal formulation was also synergistic, as demonstrated by 
the CI values. Therefore, a similar anti-cancer effect could be 
attained by lower doses of irinotecan and quercetin in this novel 
drug carrier.  
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C h a p t e r  7  




7.1 Introduction  
 
In this Chapter,  the co-encapsulation of quercetin and 
vincristine (Figure 39) in l iposomes will  be attempted in view of 
the significant synergism observed between quercetin and 
vincristine in Chapter 5. Vincristine is a vinca alkaloid derived 
from the Madagascan periwinkle. It  inhibits microtubule 
formation in mitotic spindle, arresting the dividing cells at 
metaphase (Johnson, Armstrong et al.  1963). Although 
vincristine is currently used in cancer treatment, dose-dependent 
side effects such as bone marrow suppression or neuropathy 
require patients to stop treatment. These dose-dependent side 
effects can be reduced through the use of vincristine-based 
synergistic drug combinations, whereby the same antitumor 
effect can be achieved at lower doses of vincristine, such as the 
combination of quercetin and vincristine. 
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Figure 39 Structure of vincristine. 
 
Previously, poly(D,L-lactide-co-glycolide) (PLGA) 
nanoparticles have been developed to co-encapsulate quercetin 
and vincristine (Song, Zhao et al.  2008).   Although a high 
entrapment efficiency of 92.8% was achieved for vincristine, the 
entrapment efficiency of quercetin was suboptimally at 32.7% 
only (Song, Zhao et al.  2008). In addition, both quercetin and 
vincristine were released rapidly, with around 70% of both drugs 
released in 24 hours (Song, Zhao et al.  2008). This rapid release 
from the carrier could potentially undermine the benefit  from 
enhanced permeability and retention (EPR) that allows the 
accumulation of anti-cancer drugs in tumor site (Matsumura and 
Maeda 1986). Finally, the release of quercetin and vincristine 
were not coordinated, with quercetin being released more slowly 
than vincristine (Song, Zhao et al.  2008). This could lead to non-
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synergistic molar ratios of the two compounds being released, 
potentially hampering therapeutic efficacy.  Therefore, a more 
appropriate drug carrier for the co-delivery of the 
vincristine/quercetin combination is necessary. 
In this study, vincristine was encapsulated in the aqueous 
liposomal core by remote loading using manganese sulfate and 
the A23187 ionophore (Fenske, Wong et al.  1998; Waterhouse, 
Madden et al .  2005), while quercetin was intercalated within the 
hydrophobic region of the lipid bilayer and thus solubilized by 
the same liposome carrier (Goniotaki, Hatziantoniou et al.  2004).  
The overall  aim of the current study is therefore to develop a 
physically stable liposome formulation which allows for the 
solubilization of quercetin, efficient co-encapsulation of 
quercetin and vincristine, and coordinated release of the two 
drugs such that synergism could be demonstrated using 2 human 




7.2.1 In vitro activities of quercetin and vincristine 
 
The optimal molar ratio to encapsulate quercetin and 
vincristine in the liposomes was determined by assessing the 
combined effects of quercetin and vincristine in the MDA-MB-
231 and JIMT-1 breast cancer cell  l ines. The data was analyzed 
with the median-effect principle at fixed molar ratios of 
vincristine/quercetin of 4:1, 2:1, 1:1, and 1:2. These ratios were 
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selected based on the expectation that the two drugs could be 
successfully encapsulated in the liposomes. The optimal ratio 
will be used for liposome encapsulation. Figure 40 shows the 
Combination index (CI) values at the four molar ratios of 
vincristine/quercetin at ED7 5. The CI values of 
vincristine/quercetin at molar ratios of 4:1, 2:1, 1:1 and 1:2 were 
0.41, 0.0022, 2.50 and 1.17 for JIMT-1 cells and 12.60, 0.85, 
1.09 and 1.48 for MDA-MB-231 cells.   Therefore, the most 
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Figure 40 Combination index (CI) values at ED75 for 
vincristine/quercetin exposed to JIMT-1 (white bars) and MDA-
MB-231 (black bars) breast cancer cells at molar ratios of 
vincristine/quercetin of 4:1, 2:1, 1:1 and 1:2. Each value 
represents the mean ± SEM from three independent experiments.  
CI values of 0.9-1.1 indicate additive activity, CI values < 0.9 
indicate drug synergy and values > 1.1 indicate antagonism. 
 
 
7.2.2 Quercetin incorporation into ESM liposomes and stability studies 
 
Although quercetin has been efficiently encapsulated in 
egg phosphocholine (EPC) liposomes previously (Goniotaki,  
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Hatziantoniou et al.  2004),  quercetin loading in egg 
sphingomyelin (ESM) liposomes was explored due to the 
superior in vivo  circulation lifetime of vincristine encapsulated 
into ESM/Cholesterol liposomes (Krishna, Webb et al.  2001) as 
compared to EPC/Cholesterol liposomes (Boman, Mayer et al.  
1993). The formulation comprising of 
ESM/Cholesterol/Quercetin (50:45:5 mole ratio) was initially 
used. However, due to the low encapsulation efficiency of 
quercetin (30.3%, Table 13) in the ESM/Cholesterol/Quercetin 
(50:45:5 mole ratio) liposomes, the proportions of ESM and 
quercetin was varied so as to obtain the optimal liposomal 
formulation for quercetin loading.  
Table 13 shows the quercetin loading efficiency in the 
presence of 0.0 mol%, 10.0 mol%, 15.0 mol%, 17.5 mol%, 20.0 
mol% and 45.0 mol% of cholesterol,  respectively. Overall,  
quercetin incorporation in the liposomes decreased in the 
presence of cholesterol.  The percentage of quercetin loaded in 
the liposomes was 101.8%, 93.6%, 88.4%, 81.5%, 62.9% and 
30.3% in the presence of  0.0 mol%, 10.0 mol%, 15.0 mol%, 17.5 
mol%, 20.0 mol% and 45.0 mol% of cholesterol, respectively.  In 
addition, the extent of solubilization of quercetin by liposomes 
was calculated based on the concentration of quercetin in the 
liposomes divided by the solubility of quercetin in free buffer 
(80 μM). All liposomal formulations could improve quercetin 
solubilization, ranging from 3.3 to 11.2 times (Table 13).  
 107   
In addition, the physical stability of these liposomes was 
monitored immediately after extrusion and storage for 7 days at 4 
ºC following extrusion. Although the liposomes were of similar 
sizes after extrusion, the liposomes containing less than 45.0 
mol% of cholesterol showed increases in sizes and 
polydispersities after storage at 4 ºC for 7 days (Table 14), 
suggesting liposome aggregation. Prior research has shown that 
the inclusion of PEG20 00-lipids would reduce liposome 
aggregation (Dos Santos, Allen et al.  2007). Although negatively 
charged DSPE-PEG20 00 is normally used, it  has been shown to 
increase in vivo  leakage rates of vincristine (Webb, Saxon et al.  
1998). Therefore, neutral PEG2 000-ceramide was used in the 
formulation. Quercetin incorporation was found to be not 
significantly different following PEG2 000-ceramide incorporation 
(p>0.05) (Table 13). In addition, the physical stability of these 
liposomes was monitored immediately after extrusion and 7 days 
following extrusion. There was no significant change in size and 
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Table 13 Quercetin loading efficiency (%) expressed as a 
function of the mol% cholesterol in the liposomes in the presence 




In absence of 5 mol% 
PEG20 00-ceramide 












0.0 101.8 ± 
1.8 
11.2 101.4 ± 
2.1 
11.1 
10.0 93.6 ± 
6.8 
10.3 97.2 ± 
3.2 
10.6 
15.0 88.4 ± 
1.7 
9.7 89.3 ± 
2.4 
9.8 
17.5 81.5 ± 
3.0 
8.9 78.3 ± 
1.9 
8.6 
20.0 62.9 ± 
1.5 
6.9 54.4 ± 
10.7 
6.0 
45.0 30.3 ± 
2.0 
3.3 25.7 ± 
2.2 
2.8 
For formulations without 5 mol% PEG2 000-ceramide, 
ESM/Quercetin/Cholesterol liposomes were in molar ratios of 
95:5:0, 85:5:10, 80:5:15, 77.5:5:17.5, 75:5:20 and 50:5:45. For 
formulations with 5 mol% PEG2 000-ceramide, 
ESM/Quercetin/PEG2 000-ceramide/Cholesterol liposomes were in 
molar ratios of 90:5:5:0, 80:5:5:10, 75:5:5:15, 72.5:5:5:17.5, 
70:5:5:20 and 45:5:5:45. All formulations were formulated at 
5:95 drug-to-lipid molar ratios. Each value represents the mean ± 
SEM from three independent experiments. 
  
 109   
Table 14 Physical stability of the ESM/Cholesterol/Quercetin 














0.135 ± 0.082 1120.8 
± 116.4 
1.000 ± 0.001 
10.0 131.5 
± 13.8 
0.137 ± 0.062 1320.4 
± 110.2 
1.000 ± 0.001 
15.0 158.0 
± 26.5 
0.470 ± 0.043 1034.6 
± 123.4 
0.434 ± 0.024 
17.5 141.5 
± 17.8 
0.424 ± 0.134 1043.6 
± 236.4 
0.463 ± 0.045 
20.0 200.0 
± 34.5 
0.637 ± 0.073 201.3 ± 
143.6 
0.634 ± 0.056 
45.0 145.6 
± 22.3 
0.195 ± 0.023 143.5 ± 
29.7 
0.200 ± 0.034 
ESM/Quercetin/Cholesterol liposomes were in molar ratios of 
95:5:0, 85:5:10, 80:5:15, 77.5:5:17.5, 75:5:20 and 50:5:45. All 
formulations were formulated at 5:95 drug-to-lipid molar ratios. 
Each value represents the mean ± SEM from three independent 
experiments.    
 
 
Table 15 Physical  stability of the ESM/Quercetin/PEG20 00- 
ceramide/Cholesterol liposomes immediately and 7 days after 













0.123 ± 0.002 123.9 
± 12.3 
0.132 ± 0.045 
10.0 121.5 
± 16.4 
0.100 ± 0.003 120.5 
± 13.2 
0.181 ± 0.023 
15.0 131.5 
± 14.6 
0.153 ± 0.045 134.0 
± 15.6 
0.112 ± 0.053 
17.5 135.9 
± 12.0 
0.161 ± 0.032 134.7 
± 13.2 
0.143 ± 0.043 
20.0 133.3 
± 13.5 
0.137 ± 0.034 134.5 
± 14.5 
0.146 ± 0.046 
45.0 140.6 
± 12.6 
0.172 ± 0.089 143.6 
± 16.8 
0.187 ± 0.036 
ESM/Quercetin/PEG2 000-ceramide/Cholesterol liposomes were in 
molar ratios of 90:5:5:0, 80:5:5:10, 75:5:5:15, 72.5:5:5:17.5, 
70:5:5:20 and 45:5:5:45. All formulations were formulated at 
5:95 drug-to-lipid molar ratios. Each value represents the mean ± 
SEM from three independent experiments.   
 110   
 
7.2.3 Effect of cholesterol on vincristine loading 
 
Previously, vincristine has been loaded in liposomes 
containing high concentration of cholesterol (45.0 mol%) 
(Waterhouse, Madden et al.  2005; Johnston, Semple et al.  2006). 
However, due to the low incorporation of quercetin in ESM/ 
PEG2000-ceramide liposomes containing 45.0 mol% cholesterol,  
the effect of vincristine loading with varying cholesterol levels 
was explored. Table 16 shows the effect of cholesterol on 
vincristine loading. The maximum percentage of vincristine 
loaded in the liposomes was 25.5%, 26.1%, 55.0%, 70.0%, 95.8% 
and 90.8% in the presence of  0.0 mol%, 10.0 mol%, 15.0 mol%, 
17.5 mol%, 20.0 mol% and 45.0 mol% of cholesterol,  
respectively. Therefore, vincristine loading is increased with 
higher cholesterol levels. In addition, vincristine loading 
declined with time for liposomes with cholesterol levels of 0.0 
mol%, 10.0 mol% and 15.0 mol%, but this was not observed for 
liposomes with higher cholesterol levels of 17.5 mol%, 20.0 
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Table 16 Vincristine loading efficiency (%) expressed as a 
function of the amount of cholesterol for liposomes comprising 
of ESM/PEG2 000-ceramide and varying ratios of cholesterol at 





15 30 60 90 
0.0 25.5 ± 5.5 7.2 ± 1.6 15.3 ± 3.0 8.9 ± 3.5 
10.0 26.1 ± 3.4 11.4 ± 0.8 16.2 ± 3.6 14.8 ± 0.7  
15.0 48.3 ± 4.2 55.0 ± 0.5 30.7 ± 5.4 36.1 ± 5.2 
17.5 43.7 ± 1.8 65.0 ± 2.9 67.0 ±1.2 70.0 ± 1.4 
20.0 68.7 ± 5.1 88.8 ± 5.1 90.8 ± 5.3 95.8 ± 2.4 
45.0 86.5 ± 2.0 90.7 ± 5.4 90.8± 2.9 90.0 ± 2.6 
ESM/PEG2 000-ceramide/Cholesterol were in molar ratios of 
95:5:0, 85:5:10, 80:5:15, 77.5:5:17.5, 75:5:20 and 50:5:45. Each 




7.2.4 Effect of quercetin on vincristine loading 
 
Besides the amount of cholesterol,  the presence of 
quercetin could also influence vincristine loading. This is 
because quercetin is incorporated in the lipid bilayer (Goniotaki, 
Hatziantoniou et al.  2004) and could alter the permeability of the 
liposomes, thereby affecting vincristine loading. Hence, the 
effect of quercetin incorporation on vincristine loading was also 
explored by comparing the loading of vincristine in the presence 
and absence of quercetin (Figure 41). Quercetin incorporation 
had no effect on vincristine loading at 0.0 mol%, 10.0 mol%, 
20.0 mol% and 45.0 mol% of cholesterol (Figure 41 a,b,e,f) .  
However, quercetin incorporation affected the vincristine loading 
profile at 15 mol% and 17.5 mol% of cholesterol (Figure 41 c,d). 
In the absence of quercetin, vincristine loading peaked at 30 
minutes at 59.3% but subsequently declined to 30.7% upon 
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longer incubation at 15 mol% of cholesterol (Figure 41 c).  In 
contrast,  this decline did not occur in the presence of quercetin. 
In addition, at 17.5 mol% of cholesterol,  the amount of 
vincristine loaded was higher in liposomes containing quercetin 
as compared to those without quercetin for the time points of 15, 
30 and 60 minutes (Figure 41 d). 
 












Figure 41 Comparison of vincristine loading efficiency (%) in the presence (■) and absence (∆) of 5 mol%, quercetin at 
varying cholesterol levels: (a) 0.0 mol% cholesterol,  (b) 10.0 mol% cholesterol,  (c) 15.0 mol% cholesterol,  (d) 17.5 
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7.2.5 Effect of temperature on vincristine loading  
 
Temperature  is another factor that can influence the 
efficiency of vincristine loading. Hence, a comparison was done 
between vincristine loading at 60 ºC which is above the phase 
transition temperature of ESM, and 37 ºC which is below. 
Although vincristine loading at 37 ºC prevented the decrease in 
vincristine concentration over time for formulations containing 
low levels of cholesterol,  the amount of vincristine loaded 
remained low, with the maximal loading around 30%. In 
addition, for liposomes with cholesterol levels of 20 mol% and 
45 mol%, the maximal amount of vincristine loaded was 
approximately 40%, and this level of loading is much lower as 
compared to that at 60 ºC. 











Figure 42 Comparison of vincristine loading efficiency (%) of ESM/PEG2 000-ceramide/Cholesterol/Quercetin liposomes  
at 60 ºC (■) and 37 ºC (∆).  (a) 0.0 mol% cholesterol, (b) 10.0 mol% cholesterol,  (c) 15.0 mol% cholesterol,   


















































































































































































































* * * 
* 
 116   
 
7.2.6 Physical stability of the liposomes  
  
Taking the quercetin incorporation and vincristine loading 
data together, the best formulation to co-encapsulate vincristine 
and quercetin was the ESM/Cholesterol/PEG2 000-
ceramide/Quercetin formulation at 72.5:17.5:5:5 molar ratio.  
Hence, the physical stability of these liposomes was studied for 
360 days at the storage temperature of 4 ºC. There was no 
significant change in the size (Figure 43) and polydispersity 




































Figure 43 Diameters of the ESM/PEG 
ceramide/Quercetin/Cholesterol liposomes 72.5:5:5:17.5 molar 
ratio measured with quasi-elastic light scattering over 360 days. 
Each value represents the mean ± SEM from three independent 

















Figure 44 Polydispersity of the ESM/PEG 
ceramide/Quercetin/Cholesterol liposomes 72.5:5:5:17.5 molar 
ratio measured with quasi-elastic light scattering over 360 days. 
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7.2.7 In vitro drug release of vincristine and quercetin 
 
The in vitro  drug release profiles of vincristine and 
quercetin were determined through membrane dialysis in 
0.9%w/v sodium chloride. In order to determine if the release of 
vincristine and quercetin from the co-encapsulated liposomes 
would be altered by the presence of the other drug, the in vitro 
release profile of vincristine and quercetin in co-encapsulated 
liposomes were compared with liposomes comprising of 
vincristine and quercetin only. As shown in Figure 45, the 
release of quercetin was unchanged by the presence of 
vincristine (p>0.05). In contrast,  the release of vincristine was 
altered by the presence of quercetin (Figure 46). In the presence 
of quercetin, vincristine release was  slowed down to 57.7% and 
65.9% in 48 and 72 hours as compared to 86.5% and 96.6% in the 
absence of quercetin, respectively (p<0.05). The data 
demonstrated sustained release of vincristine and quercetin over 
72 hours and coordinated release of both drugs, with the optimal 
ratio for drug synergism of 2:1 maintained for the duration of the 
study (Figure 47). 
Finally, the kinetics of drug release was determined by 
fitting the data into the most common models of drug release, 
namely, zero order, first  order and square root of t ime release. 
For all  the preparations, the best fit  was observed for first  order 
kinetics (Table 17 and Table 18). The r2 values for quercetin 
release for liposomes containing quercetin only and the co-
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encapsulated preparation were 0.89 and 0.83 respectively. The r2 
values for vincristine release for liposomes containing 
vincristine only and the co-encapsulated preparation were 0.85 
and 0.87, respectively.  
 



































Figure 45  In vitro  release profile of quercetin from liposomes 
loaded with quercetin only (∆) and loaded with both vincristine 
and quercetin (■) at  37°C in 0.9%w/v sodium chloride 
determined with dialysis membrane. The liposome lipid 
composition consisted of ESM/Quercetin/PEG2 000-
ceramide/Cholesterol (72.5:5:5:17.5 molar ratio). Each value 



































Figure 46 In vitro  release profile of vincristine from liposomes 
loaded with vincristine only (∆) and loaded with both vincristine 
and quercetin (■) at  37°C in 0.9%w/v sodium chloride 
determined with dialysis membrane. The liposome lipid 
composition consisted of ESM/Quercetin/PEG2 000-
ceramide/Cholesterol (72.5:5:5:17.5 molar ratio). Each value 
represents the mean ± SEM from three independent experiments.  
* p < 0.05. 
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Table 17 r2  values of zero order, first  order and square root of 




Table 18 r2  values of zero order, first  order and square root of 






























Figure 47 Ratio of vincristine/quercetin released over 72h. The 
ratio of drug released was close to the initial loading 
vincristine/quercetin ratio of 2:1. The ratios were obtained by 
dividing the drug-lipid-ratios of vincristine by that of quercetin. 
Each value represents the mean ± SEM from three independent 
experiments, p>0.05. 
 










No vincristinea  0.75 0.89 0.78 
Vincristineb 0.70 0.83 0.74 
aESM/Quercetin/PEG2 000-ceramide/Cholesterol 72.5:5:5:17.5 
molar ratio liposomes. 
bESM/Quercetin/PEG2 000-ceramide/Cholesterol 72.5:5:5:17.5 
molar ratio liposomes containing  vincristine. 





of time drug 
release 
No quercetina 0.72 0.85 0.79 
Quercetinb 0.77 0.87 0.78 
aESM/PEG2 000-ceramide/Cholesterol 77.5:5:17.5 molar ratio 
liposomes. 
bESM/Quercetin/PEG2 000-ceramide/Cholesterol 72.5:5:5:17.5 
molar ratio liposomes. 
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7.2.8 In vitro cytotoxicity studies 
 
In order to determine if the liposome carrier comprising of 
ESM/PEG2 000-ceramide/Cholesterol (77.5:5:17.5 molar ratio) 
contributed to the cytotoxicity of the cells,  in vitro cytotoxicity 
studies were conducted with these liposomes on the MDA-MB-
231 and JIMT-1 cells.  There was no significant effect on the cell 
kill  by the lipids (Figure 48). Subsequently, l iposomes 
encapsulating vincristine or quercetin alone or the drug 
combination were diluted serially and exposed to both the MDA-
MB-231 and JIMT-1 breast cancer cell lines for 72 hours. The 
drugs were diluted by serial  dilutions. When vincristine and 
quercetin were co-encapsulated, the concentrations of vincristine 
and quercetin required to attain 75% cell kill  were reduced by 
approximately  2 log-fold as compared to monotherapy (Figure 
49) in JIMT-1 cells.  In addition, the CI was 0.12 (very 
synergistic) at ED7 5. For the MDA-MB-231 cell l ine, the 
concentrations of vincristine and quercetin required to attain 
75% cell kill  were reduced approximately 1 log-fold as compared 
to monotherapy for quercetin and 2 folds for vincristine (Figure 
50). In addition, the CI was 0.83 (synergistic) at ED7 5. Similar 
trends were observed at other ED values in both cell  l ines in 


















































Figure 48 In vitro  cytotoxicity of the liposome carrier in (a) 
MDA-MB-231 and (b) JIMT-1 cells. 






































Figure 49 Plot of vincristine and quercetin concentrations needed 
to achieve 75% cell kill in JIMT-1 cells.  Data were obtained with 
the CalcuSyn® software which uses the median dose effect 
method developed by Chou and Talalay to determine the 
Combination index. Each value represents the mean ± SEM from 












































Figure 50 Plot of vincristine and quercetin concentrations needed 
to achieve 75% cell kill  in MDA-MB-231 cells.  Data were 
obtained with the CalcuSyn® software which uses the median 
dose effect method developed by Chou and Talalay to determine 
the Combination index. Each value represents the mean ± SEM 
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7.3 Discussion 
 
An appropriately designed drug delivery system can be 
used to coordinate the release of drugs in their synergistic ratios, 
allowing for the drug combination to achieve its maximal 
therapeutic efficacy. Liposomes were selected as the drug 
delivery system to co-encapsulate vincristine and quercetin due 
to the presence of a hydrophilic liposome core and a hydrophobic 
lipid bilayer, which makes it  suitable for the co-encapsulation of 
amphipathic and hydrophobic drugs simultaneously. 
A physically stable combination liposomal formulation 
that solubilized quercetin, efficiently co-encapsulated vincristine 
and quercetin and also coordinated the release of the two drugs 
such that synergism was demonstrated in vitro has been 
developed. A drug delivery system that coordinates the release of 
vincristine and quercetin is crucial,  as illustrated by Figure 40 ,  
where a slight change in the vincristine/quercetin molar ratio 
from 2:1 to 1:1 shifted the combination effect of the two drugs 
from synergism to antagonism. Therefore, the previous 
formulation of PLGA nanoparticles, which failed to coordinate 
the release of vincristine and quercetin (Song, Zhao et al.  2008) 
may not exert i ts full  antitumor potential due to the narrow range 
in which synergism occurs.  
The liposomal formulation developed maintained the 
synergistic ratio of vincristine/quercetin 2:1 throughout the 
entire duration of the in vitro study. This ratio was maintained 
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for a sufficiently long period for synergism to be exerted, as 
shown by the CI value of 0.12 for JIMT-1 cells and 0.83 for 
MDA-MB-231 cells. This means that the doses needed to achieve 
the same cell  kill  was reduced. This could reduce the incidence 
of dose-dependent side effects associated with vincristine such 
as neurotoxicity and potentially allow for the same therapeutic 
effect to be attained with fewer side effects as compared to 
monotherapy.  
The development of a liposomal formulation which 
coordinates the release of both vincristine and quercetin is 
challenging due to the hydrophobic nature of quercetin and the 
amphipathic nature of vincristine, which requires the 
optimization of formulation variables to co-encapsulate the two 
drugs efficiently together. For example, quercetin incorporation 
and solubilization was found to be most efficient either in the 
absence or at low levels of cholesterol, possibly due to the 
competition of cholesterol and quercetin for the same 
hydrophobic space in the lipid bilayer (Goniotaki, Hatziantoniou 
et al.  2004). Quercetin penetration into the lipid bilayer would 
also be interfered by the reduced flexibility of the hydrocarbon 
chains of the lipids after cholesterol addition (Demel and De 
Kruyff 1976). In contrast ,  efficient and stable vincristine loading 
required at least 17.5 mol% of cholesterol.  This could be due to 
the higher permeability of liposomes with low cholesterol levels 
as compared to liposomes with higher cholesterol levels,  leading 
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to the leakage of manganese sulfate from the core of the 
liposomes and the elimination of the transmembrane pH gradient 
driving vincristine into the liposomes (Dos Santos, Waterhouse 
et al.  2005). 
However, with 17.5 mol% of cholesterol,  the liposomes 
were physically unstable and increased in size and 
polydispersity, although this was not observed at higher 
cholesterol levels of 45.0 mol%. This could be due to the ability 
of high levels of cholesterol to decrease the attractive van der 
Waals forces while increasing the net repulsive forces, thereby 
reducing the tendency for liposomal aggregation and fusion as 
compared to lower cholesterol concentrations (Souza and 
Teschke 2003). Although the inclusion of cholesterol could 
increase the physical stability of  liposomes, high cholesterol  
levels reduced quercetin loading and had also been shown to 
reduce the retention of some other drugs such as floxuridine 
(Tardi,  Gallagher et al.  2007). This warrants alternative methods 
for increasing liposome physical stability. Therefore, PEG2 000-
conjugated lipids, which confer physical stability through steric 
stabilization, were added to the formulation (Dos Santos, Allen 
et al .  2007). Although negatively charged DSPE-PEG2 000 lipid is 
conventionally used, it  has been shown to increase vincristine 
release from liposomes (Webb, Saxon et al.  1998). Therefore, the 
neutral PEG2 000-ceramide lipid was used instead. Besides 
preventing liposome aggregation, the inclusion of PEG2 000-
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ceramide had no adverse effect on quercetin loading. In addition, 
there was no significant change in size and polydispersity of the 
liposomes over 360 days. Therefore, PEG200 0-ceramide lipids 
could be used in place of cholesterol to stabilize liposomes from 
physical aggregation without affecting the incorporation of 
hydrophobic drugs in the lipid bilayer.  
The effect of temperature on vincristine loading was also 
explored as a possible avenue to improve vincristine loading. At 
37 ºC, slightly below the phase transition temperature of ESM, 
the amount of vincristine loaded was low (maximal loading was 
around 40%). The low amount of vincristine loaded could be 
attributed to the impedance of vincristine diffusion due to the 
tightly packed and fully extended configuration of the 
hydrocarbon chains of the lipids below the phase transition 
temperature.  
In addition, it  was shown for the first  t ime that the 
incorporation of quercetin could alter the loading and release of 
vincristine. Quercetin incorporation not only increased 
vincristine loading but also reduced vincristine release from the 
liposomes, possibly through the formation of intermolecular 
hydrogen bonds which rigidified the liposomal membrane 
(Tsuchiya, Nagayama et al.  2002) and reduced the permeability 
of the liposomal membrane to vincristine during loading and 
release. It  is worthwhile to note that despite this, the kinetics of 
drug release remained as first ordered, with the maintenance of 
 129   
the synergistic ratio of vincristine and quercetin release over 72 
hours. This is crucial in maximizing the therapeutic activity of 
the drug combination. The alteration of drug release by quercetin 
is anticipated to also apply to other membrane permeable 
amphipathic drugs similar to vincristine. Therefore, in addition 
to changing lipid composition (Waterhouse, Madden et al.  2005), 
the formation of drug precipitates (Drummond, Hayes et al .  
2007) and changes in pH gradient (Dos Santos, Cox et al.  2004), 
which are traditional methods of altering drug release, the 
incorporation of quercetin or other compounds that can form 
hydrogen bonds represent a new avenue to alter drug loading and 
release profiles. In contrast,  the observation that vincristine 
loading had no significant effect on quercetin release is 
expected, as vincristine is incorporated in the aqueous core of 
the liposomes (Johnston, Semple et al.  2006) and is unlikely to 
interfere with the release of quercetin in the lipid bilayer 
(Goniotaki, Hatziantoniou et al.  2004). 
In this Chapter, a novel drug delivery carrier which co-
encapsulated two drugs exhibiting synergism, coordinated the 
drug release profiles of vincristine and quercetin and prolonged 
the exposure times for both drugs had been developed.  The fixed 
ratio was maintained for a sufficiently long period for synergism 
to be exerted as shown by the in vitro data, allowing for optimal 
anti-cancer activity to be attained in MDA-MB-231 and JIMT-1 
cells.   
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Table 19 summarizes the CI values of irinotecan/quercetin 
and vincristine/quercetin liposomes in MDA-MB-231 and JIMT-1 
cells from Section 6.2.7 and Section 7.2.8.  From the CI values, 
the most active combination was the vincristine/quercetin 
combination in JIMT-1 cells.  In view of the significant 
synergism of this preparation, the therapeutic efficacy of 
vincristine/quercetin liposomes will  be assessed in the JIMT-1 
breast cancer xenograft in Chapter 9.   
 
Table 19 Summary of CI values of irinotecan/quercetin and 
vincristine/quercetin liposomes in MDA-MB-231 and JIMT-1 






MDA-MB-231 cells 0.72 0.83 
JIMT-1 cells 0.49 0.12 
aIrinotecan was encapsulated in DPPC/DSPE-PEG2 000/Quercetin 
90:5:5 molar ratio liposomes.  
bVincristine was encapsulated in Egg Sphingomyelin 
(ESM)/Cholesterol/N-palmitoyl-sphingosine-1-
{succinyl[methoxy(polyethylene glycol)200 0] (PEG200 0-
ceramide)/Quercetin 72.5:17.5:5:5 molar ratio  liposomes.  
 
In addition, the plasma elimination profiles of vincristine 
and quercetin will  also be assessed. However, since there is no 
published method to simultaneously determine vincristine and 
quercetin in biological fluids, therefore method development and 
validation to determine vincristine and quercetin in plasma 
biological fluids will  be conducted in the next Chapter.  
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C h a p t e r  8  
SIMULTANEOUS DETERMINATION OF VINCRISTINE AND 
QUERCETIN IN PLASMA AND TISSUE HOMOGENATE BY 




8.1 Introduction  
 
As mentioned in the last Chapter,  no published method is 
available to determine vincristine and quercetin levels together 
in plasma and organ homogenates. Previously, quercetin in 
plasma alone has been quantified by high performance liquid 
chromatography (HPLC) with ultra-violet (uv) detection (Jones 
1998; Khaled and El-Sayed 2000; Yang 2005; Zhigaltsev, Maurer 
et al.  2005; Yang, Liu et al.  2007; Li, Yang et al.  2009; Tang, 
Yin et al.  2009) or HPLC with electrochemical detection (Chen 
2005). Vincristine in plasma alone has been quantified by HPLC 
with uv detection (Noble, Guo et al.  2009), LC/MS (Corona, 
Casetta et al.  2008), LC/MS/MS (Guilhaumou, Solas et al.  2010) 
and radioactive methods (Boman, Mayer et al.  1993). Although a 
HPLC method had been described for quantifying vincristine and 
quercetin in nanoparticles,  there was insufficient provided on the 
mobile phase and HPLC conditions used. Most importantly, no 
internal standard was used (Song, Zhao et al.  2008). The 
presence of an internal standard for pharmacokinetic studies 
allows for the correction of errors due to sample preparation, 
leading to more accurate values. Hence, there is a need to 
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develop and validate a method to simultaneously quantify 
vincristine and quercetin in vivo.   
Ultra performance liquid chromatography (UPLC) is a 
chromatographic system which has been shown to improve the 
resolution, sensitivity, speed and reduce solvent consumption 
(Mazzeo, Neue et al.  2005; Swartz 2005; Nováková, Matysová et 
al.  2006). In view of these advantages, a simple, simultaneous 
and rapid UPLC method so as to quantify vincristine and 
quercetin levels in plasma for use in pharmacokinetic study in 




8.2.1 Optimization of analysis conditions 
 
Apigenin was used as the internal standard (Figure 51). 
Initially, isocractic flow comprising of 75% milli-Q water (A) 
and 25% acetonitrile (B)  was attempted. However, the 
chromatographic run time was more than 10 minutes. In addition, 
the vincristine peak displayed tailing. Therefore, 0.1% formic 
acid was added to both mobile phase A and B to reduce tailing.  
Gradients that have been attempted ranged from (1) 75% A 
(0-3min), followed by 70% A to 50% A (3-9 min), 50% A to 5% 
A (9-10 min); (2) 75% A (0-3min), 70% A to 30% A (3-9 min) 
and 30% A to 5% A (9-10 min); (3) 75% A (0-3 min), 70% A to 
30% A (3-7 min) and 30% A to 5% A (7-8 min); (4) 75% A to 5% 
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A (0-3.8 min), 5% A (3.81-4.1 min). For all  modes, the mobile 
phase was reset to initial conditions of 75% A for 0.6 minutes 
before the next injection.  Mode 4 was the optimal gradient 
which showed shortest run time and good separation of the 
analytes. Although all  three compounds could be detected at 297 
nm (Figure 52), quercetin was quantified at 376 nm to increase 
sensitivity of the method (Figure 53). At 376 nm, the vincristine 
peak could not be detected. The retention times of quercetin, 





Figure 51  Structure of apigenin (internal standard).
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Figure 52 Representative chromatograms of (a) quercetin, (b) apigenin (internal standard), (c) vincristine and (d) 
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Figure 53 Representative chromatograms of (a) quercetin, (b) apigenin (internal standard), (c) vincristine (not detected) 
and (d) quercetin, apigenin and vincristine mixture at 376 nm.
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(b) (d) 
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8.2.2 Specificity in plasma samples 
 
Figure 54 a and b  show representative chromatograms of 
blank plasma at 297 and 376 nm, respectively. In addition, 
Figure 54 c and d  show representative chromatograms of blank 
plasma spiked with quercetin, vincristine and apigenin (internal 
standard) at 297 nm and 376 nm, respectively, after l iquid-liquid 
extraction with ethyl acetate. There were no peaks interfering 
with quercetin, apigenin and vincristine in blank mouse serum at 
both wavelengths. 





Figure 54. Chromatograms of (a) blank mouse serum at 297 nm, (b) blank mouse serum at 376 nm, (c) blank mouse 
serum spiked with vincristine, quercetin and internal standard at 297 nm and (d) blank mouse serum spiked with 
vincristine, quercetin and internal standard at 376 nm.
(a) (c) 
(b) (d) 
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8.2.3 Linearity in plasma samples  
 
The average calibration equation relating y (peak area 
ratio of drug:internal Standard) to x (concentration) was 
calculated from five analytical runs at the five concentrations 
cited above were as follows: (i) quercetin: y= 2.6494x – 0.1465, 
range of linearity from 0.22 to 17.74 nmol/mL, r2  = 1.000 ;  (ii) 
vincristine: y=0.34689x – 0.0056, range of linearity from 0.17 to 
54.17 nmol/mL, r2  = 0.999. The limits of detection for vincristine 
and quercetin were 0.11 nmol/mL and 0.06 nmol/mL, 
respectively. The limits of quantitation for quercetin and 
vincristine were 0.22 nmol/mL and 0.17 nmol/mL, respectively. 
 
8.2.4 Accuracy and precision in plasma samples 
 
Table 20  summarizes the intra-day analytical accuracy and 
precision (expressed as coefficient of variation, CV) of 
vincristine and quercetin. For quercetin, the intra-day accuracy 
ranged from 99.8% to 105.2% and its intra-day CV ranged from 
2.4% to 3.3%. For vincristine, the intra-day accuracy ranged 
from 95.2% to 108.6% and its intra-day CV ranged from 1.5% to 
14.9%.   Table 21  summarizes the inter-day analytical accuracy 
and precision of vincristine and quercetin. The inter-day 
accuracy of quercetin ranged from 95.9% to 103.9% respectively 
and the inter-day CV ranged from 6.5% to 9.3%. For vincristine, 
inter-day accuracy ranged from and 98.1% to 108.8% 
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respectively and the inter-day CV ranged from 9.1% to 15.5%. 
The results indicate that the method had satisfactory accuracy 
and precision. 
 















Quercetin 14.19 14.16 99.8 2.4 
 7.10 7.25 102.1 3.3 
 1.77 1.84 103.7 2.5 
 0.22 (LLOQ) 0.23 105.2 3.1 
Vincristine 43.34 43.64 100.7 4.3 
 10.83 11.27 104.1 3.5 
 2.71 2.58 95.2 1.5 
 0.17 (LLOQ) 0.18 108.6 14.9 
CV: coefficient of variation  
LLOQ: lower limit of quantification 
 
 













Quercetin 14.19 14.03 98.9 6.5 
 7.10 7.38 103.9 8.5 
 1.77 1.77 100.2 9.2 
 0.22 (LLOQ) 0.21 95.9 9.3 
Vincristine 43.34 43.12 99.5 9.1 
 10.83 11.35 104.8 12.3 
 2.71 2.66 98.1 13.2 
 0.17 (LLOQ) 0.18 108.8 15.5 
CV: coefficient of variation  
LLOQ: lower limit of quantification 
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8.2.5 Extraction efficiency in plasma samples  
 
Table 22  shows the absolute recoveries of vincristine and 
quercetin. Absolute recoveries were in the range of 96.7% to 
120.0% for quercetin and 103.2% to 104.8% for vincristine. The 
CVs were in the range of 8.8% to 14.3% for quercetin and 12.7% 
to 15.5% for vincristine. Hence, simple liquid-liquid extraction 
from plasma with ethyl acetate is efficient for both vincristine 
and quercetin. 
 















Quercetin 14.19 13.84 97.5 8.8 
 7.10 6.87 96.7 13.9 
 1.77 1.73 97.8 9.79 
 0.22 (LLOQ) 0.26 120.0 14.3 
Vincristine 43.34 44.86 103.5 12.7 
 10.83 11.32 104.5 13.2 
 2.71 2.53 104.8 14.6 
 0.17 (LLOQ) 0.18 103.2 15.5 
CV: coefficient of variation 
LLOQ: lower limit of quantification 
 
 
8.2.6 Stability in plasma samples 
 
The stability of vincristine and quercetin in plasma 
samples was accessed after 24h at 4 ºC. They were stable and the 
CVs were in the range of 9.5% to 14.3% for quercetin and 10.5% 
to 15.5% for vincristine (Table 23). 
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Table 23 The stability of quercetin and vincristine in prepared 









Quercetin 14.19 14.07 9.5 
 7.10 6.75 13.6 
 1.77 1.74 12.2 
 0.22 (LLOQ) 0.23 14.3 
Vincristine 43.34 43.39 12.2 
 10.83 11.75 10.5 
 2.71 2.83 10.8 
 0.17 (LLOQ) 0.17 15.5 
CV: coefficient of variation 
LLOQ: lower limit of quantification 
 
 
8.2.7 Specificity for the liver and spleen homogenates 
 
Figure 55  a and b  show representative chromatograms of 
blank liver homogenate at 297 and 376 nm, respectively and 
Figure 55c and d  show representative chromatograms of 
homogenate spiked with quercetin, vincristine and apigenin 
(internal standard) at  297 nm and 376 nm, respectively, after 
liquid-liquid extraction with ethyl acetate.  
Similarly, Figure 56 a and b  show representative 
chromatograms of blank spleen homogenate at 297 nm and 376 
nm, respectively. Figure 56  c and d show representative 
chromatograms of homogenate spiked with quercetin, vincristine 
and apigenin (internal standard) at 297 nm and 376 nm, 
respectively, after l iquid-liquid extraction with ethyl acetate. 
There were no peaks interfering with quercetin, apigenin and 
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vincristine in blank liver and spleen homogenate at both 
wavelengths.





Figure 55 Chromatograms of (a) blank liver homogenate at 297 nm, (b) blank liver homogenate at 376 nm, (c) blank 
liver homogenate spiked with vincristine, quercetin and internal standard at 297 nm and (d) blank liver homogenate 
spiked with vincristine, quercetin and internal standard at 376 nm.
(a) (c) 
(b) (d) 




Figure 56 Chromatograms of (a) blank spleen homogenate at 297 nm, (b) blank spleen homogenate at 376 nm, (c) blank 
spleen homogenate spiked with vincristine, quercetin and internal standard at 297 nm and (d) blank spleen homogenate 
spiked with vincristine, quercetin and internal standard at 376 nm.
(a) (c) 
(b) (d) 
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8.2.8 Linearity in liver and spleen homogenates 
 
For the liver, the average calibration equation relating y 
(peak area ratio of drug:internal standard) to x (concentration) 
was calculated from five analytical runs at five concentrations as 
follows: (i) quercetin: y = 6.1628x + 0.4028, range of linearity 
from 0.22 to 17.74 nmol/mL, r2  = 0.999 ;  (i i) vincristine y = 
1.3902x + 0.0521, range of linearity from 0.17 to 54.17 
nmol/mL, r2  = 0.995.  
For the spleen, the average calibration equation relating y 
(peak area ratio of drug: internal standard) to x (concentration) 
was calculated from five analytical runs at five concentrations as 
follows: (i) quercetin: y = 6.6133x – 0.0032, range of linearity 
from 0.22 to 17.74 nmol/mL, r2=0.999; (ii) vincristine y = 
1.5128x + 0.1987, range of linearity from 0.17 to 54.17 
nmol/mL, r2  = 0.994. In addition, the limits of detection for 
quercetin and vincristine for both tissue homogenates were 0.17 
nmol/mL and 0.22 nmol/mL, respectively. 
 
8.2.9 Accuracy and precision in liver and spleen homogenates 
 
Table 24  and  Table 25  summarize the intra- and inter-day 
analytical accuracy and precision (expressed as CV) in liver 
homogenate. For the liver homogenate, the intra-day accuracy for 
quercetin ranged from 91.8% to 105.3% and the corresponding 
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CV ranged from 4.8% to 10.1%. For vincristine, the intra-day 
accuracy ranged from 93.6% to 115.6% and the corresponding 
CV ranged from 0.4% to 19.1%. In addition, the inter-day 
accuracy of quercetin ranged from 80.0% to 110.2% and the 
corresponding CV ranged from 2.9% to 9.3%. For vincristine, the 
inter-day accuracy of vincristine ranged from 100.2% to 109.4% 
and the corresponding CV ranged from 0.6% to 9.0% The results 
indicate that the method had satisfactory accuracy and precision. 
 












Quercetin 14.19 13.03 91.8 5.0 
 7.10 7.14 100.6 4.8 
 1.77 1.86 105.3 6.6 
 0.22 (LLOQ) 0.21 95.5 10.1 
Vincristine 43.34 43.77 101.0 0.4 
 10.83 11.57 106.8 6.8 
 2.71 3.13 115.6 14.6 
 0.17 (LLOQ) 0.16 93.6 19.1 
CV: coefficient of variation 
LLOQ: lower limit of quantification 
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Table 25 Inter-day precision of quercetin and vincristine in liver 












Quercetin 14.19 13.76 97.0 2.9 
 7.10 7.72 108.7 3.5 
 1.77 1.95 110.2 2.5 
 0.22 (LLOQ) 0.176 80.0 9.3 
Vincristine 43.34 43.94 101.4 0.6 
 10.83 11.84 109.4 4.7 
 2.71 3.64 104.2 6.5 
 0.17 (LLOQ) 0.17 100.2 9.0 
CV: coefficient of variation 
LLOQ: lower limit of quantification 
 
For spleen homogenate, the intra-day accuracy for 
quercetin ranged from 85.0% to 112.6% and the corresponding 
CV ranged from 1.6% to 4.2%. The intra-day accuracy for 
vincristine ranged from 102.2% to 115.0% and the corresponding 
CV ranged from 0.6% to 2.4% (Table 26). The inter-day accuracy 
for quercetin ranged from 86.7% to 114.9% and the 
corresponding CV was in the range of 0.9% to 6.0%. For 
vincristine, the inter-day accuracy ranged from 102.5% to 
107.2% and the corresponding CV was in the range of 1.2% to 
10.3% (Table 27).  
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Table 26 Intra-day precision of quercetin and vincristine in 











Quercetin 14.19 14.78 104.3 1.6 
 7.10 8.71 112.6 2.1 
 1.77 1.51 85.0 2.8 
 0.22 (LLOQ) 0.22 98.3 4.2 
Vincristine 43.34 44.30 102.2 0.6 
 10.83 12.20 112.7 1.1 
 2.71 3.33 112.8 1.8 
 0.17 (LLOQ) 0.20 115.0 2.4 
CV: coefficient of variation 




Table 27  Inter-day precision of quercetin and vincristine in 











Quercetin 14.19 15.11 106.5 0.9 
 7.10 8.87 114.9 2.7 
 1.77 1.50 86.7 4.4 
 0.22 (LLOQ) 0.21 95.5 6.0 
Vincristine 43.34 44.42 102.5 1.2 
 10.83 11.49 106.1 1.7 
 2.71 2.91 107.2 10.3 
 0.17 (LLOQ) 0.18 106.5 5.4 
CV: coefficient of variation 
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8.2.10 Recovery in liver and spleen homogenates 
 
Table 28 shows the absolute recovery of quercetin and 
vincristine in liver,  in which absolute recoveries were in the 
range of 98.3% to 119.7% for quercetin and 83.8% to 114.7% for 
vincristine. For spleen, absolute recoveries were in the range of 
94.3% to 109.7% for quercetin and 106.1% to 121.2% for 
vincristine (Table 29).  Hence, simple liquid-liquid extraction 
from the liver with ethyl acetate is efficient for both quercetin 
and vincristine. 
 
Table 28 Extraction efficiency of quercetin and vincristine in 















Quercetin 14.19 13.95 98.3 2.4 
 7.10 7.55 106.3 2.3 
 1.77 2.12 119.7 11.3 
 0.22 (LLOQ) 0.22 98.7 8.7 
Vincristine 43.34 44.34 102.3 1.3 
 10.83 9.70 89.6 8.6 
 2.71 2.27 83.8 3.8 
 0.17 (LLOQ) 0.20 114.7 2.3 
CV: coefficient of variation 
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Table 29 Extraction efficiency of quercetin and vincristine in 















Quercetin 14.19 14.74 103.9 1.8 
 7.10 7.79 109.7 12.2 
 1.77 1.67 94.3 9.4 
 0.22 (LLOQ) 0.22 99.6 16.3 
Vincristine 43.34 45.98 106.1 5.7 
 10.83 12.31 113.7 1.7 
 2.71 3.28 121.2 1.3 
 0.17 (LLOQ) 0.18 108.2 3.7 
CV: coefficient of variation 
LLOQ: lower limit of quantification 
  
8.2.11 Stability in liver and spleen homogenates 
 
The stability of quercetin and vincristine in homogenate 
samples was accessed after 24h at 4 ºC. The liver homogenate 
samples were stable and the CV% were in the range of 2.4% to 
10.5% for quercetin and 1.6% to 5.5% for vincristine (Table 30). 
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Table 30 The stability of quercetin and vincristine in liver 









CV (%)  
 
Quercetin 14.19 13.97 10.5 
 7.10 7.34 2.4 
 1.77 2.01 3.8 
 0.22 (LLOQ) 0.18 3.5 
Vincristine 43.34 43.70 2.0 
 10.83 12.41 2.3 
 2.71 3.18 1.6 
 0.17 (LLOQ) 0.19 5.5 
CV: coefficient of variation 
LLOQ: lower limit of quantification  
 
The spleen homogenate samples were stable and the CV% 
were in the range of 0.5% to 4.0% for quercetin and 0.8% to 
9.9% for vincristine (Table 31).  
 
Table 31 The stability of quercetin and vincristine in spleen 












Quercetin 14.19 14.29 0.5 
 7.10 8.12 4.0 
 1.77 1.58 2.5 
 0.22 (LLOQ) 0.25 1.3 
Vincristine 43.34 42.77 0.8 
 10.83 12.25 0.6 
 2.71 3.45 6.9 
 0.17 (LLOQ) 0.22 9.9 
CV: coefficient of variation 
LLOQ: lower limit of quantification  
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8.3 Discussion 
 
Due to the lack of published methods, it  was necessary to 
develop a method to quantify quercetin and vincristine in plasma 
and other tissue homogenates. In addition, method validation was 
done to assess its reliability. Validation was necessary for the 
acquisition of high quality data so that meaningful conclusions 
can be drawn. Therefore, validation was done in accordance with 
Food and Drug Administration (FDA) guidelines (Administration 
2001).   Under these guidelines, the mean values have to be 
within 15% except at LLOQ, where the mean values have be 
within 20% for accuracy. For precision, the values should not 
exceed 15% CV except at LLOQ, where it  should not exceed 20% 
CV. In addition, selectivity and stability of the method have to 
be determined.  
The mean values and the CV% values obtained in this 
Chapter conformed to FDA guidelines. The chromatographs of 
the blank plasma and tissue homogenates show that there was no 
interference with endogeneous substances and the analytes was 
stable for 24 hours, fulfilling FDA guidelines. Results show that  
a simple, fast,  accurate UPLC method for determination of 
quercetin and vincristine in mouse plasma samples and tissue 
homogenates has been developed and validated. The method has 
good calibration fit ,  precision, accuracy and recovery. This 
method will be applied to quantify quercetin and vincristine 
levels in the subsequent Chapter.  
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C h a p t e r  9  
IN VIVO  STUDIES WITH QUERCETIN AND VINCRISTINE 
 
 
9.1 Introduction  
 
In Chapter 7, l iposomes comprising of Egg Sphingomyelin 
(ESM)/Cholesterol/N-palmitoyl-sphingosine-1-
{succinyl[methoxy(polyethylene glycol)20 00] (PEG2 000-
ceramide)/Quercetin (72.5:17.5:5:5 mole ratio) were found to co-
encapsulate quercetin and vincristine efficiently, display 
coordinated release of both drugs in vitro ,  and the formulation 
was active against MDA-MB-231 and JIMT-1 breast cancer cells.  
The aims of this Chapter are (1) to compare the plasma 
elimination profiles of the free drug combination with the 
liposome co-encapsulated formulation, (2) to determine whether 
the liposomal formulation can maintain the optimal synergistic 
ratio in vivo ,  and (3) to assess the antitumor efficacy of this 
formulation as compared to the free drug combination in a human 
xenograft model.  As mentioned in Section 7.3, the JIMT-1 breast 
tumor xenograft model will be used because the in vitro  data 
from Chapter  7 indicated that the vincristine/quercetin 
combination was more active against the JIMT-1 cell l ine as 
compared to MDA-MB-231. In addition, JIMT-1 also represents 
the ER-, PR- and transtuzumab-insensitive breast cancer subtype, 
where currently there are no effective treatment options available 
(Dizdar and Altundag 2010). Thus, it  is worthwhile to explore 
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the vincristine/quercetin combination as a possible treatment 




9.2.1 Plasma elimination profile of free and liposomal combination of 
quercetin and vincristine 
 
The plasma elimination profiles of free versus liposomal 
encapsulated quercetin and vincristine were determined in Balb/c 
mice. Figure 57 shows that free quercetin and vincristine levels 
were undetectable after 60 minutes and 120 minutes, 
respectively, whilst the levels of quercetin and vincristine in the 
liposome group remained detectable throughout the entire study 
period. In addition, quercetin and vincristine co-encapsulated in 
liposomes also had longer half lives, higher maximal 
concentration in plasma (Cma x), higher total area under the curve 
(AUCt o t a l) ,  higher mean residence time (MRTl as t) ,  and lower 
clearance (Cl) as compared to the free drug combination (Table 
32). In addition, Figure 58 shows that the initial encapsulated 
ratio of 2:1 vincristine/quercetin was maintained over the entire 
study period for the liposomal formulation (p>0.05) but not for 
the free drug combination (p<0.05).  
































Figure 57 Concentrations of quercetin and vincristine in the 
plasma of Balb/c mice after intravenous administration of free 
combination of quercetin and vincristine or quercetin and 
vincristine co-encapsulated in liposomes. Concentrations of free 
quercetin are represented by (♦),  free vincristine by (▲),  
l iposomal quercetin by (◊) and liposomal vincristine by (∆).  Each 
value represents the mean ± SEM from 4 samples. 
 
 
Table 32 Summary of pharmacokinetic parameters for quercetin 
and vincristine.  
 
  Free Liposomal 
  Quercetin Vincrist ine Quercetin Vincrist ine 
Cma x  
(nmol/mL) 2.07 0.19 19.20 34.10 
AUCl a s t  
(μmol.h/mL) 6.65 0.33 604.16 1240.54 
 t1 /2  (h) 1.49 0.48 14.20 16.00 
Cl (mL/h) 0.47 16.90 0.01 0.01 
MRTl as t  (h) 1.20 0.40 9.22 8.26 
V (mL/g) 1.00 12.19 0.08 0.09 
r -0.82 -0.92 -0.84 -0.96 
Mice (n=4) received the free combination of 1.33 mg/kg 
vincristine and 0.24 mg/kg quercetin (2:1 vincristine/quercetin 
mole ratio) or 1.33 mg/kg vincristine and 0.24 mg/kg quercetin 
co-encapsulated into liposomes. Injection volumes were 200 
μL. Pharmacokinetic parameters were obtained from the pooled 
data from 4 mice. Cma x: Maximum plasma concentration of 
drug,  AUCl a s t :  Area under the curve computed to the last  
observation,  t1 / 2:  half l ife,  Cl: total body clearance, MRTl as t :  
Mean residence time up to the last observation,V: Volume of 
distribution,   r:  l inear correlation coefficient. 
 





























Figure 58 Comparison of the ratio of vincristine/quercetin over 
time for free vincristine and quercetin combination (■) and 
vincristine/quercetin in co-encapsulated liposomes (♦) in plasma. 
The dotted line represents the initial ratio of 
vincristine/quercetin. Each value represents the mean ± SEM 
from 4 samples. * p < 0.05. 
 
 
9.2.2 Drug accumulation in the reticuloendothelial system 
 
Liposomes are mostly eliminated by the liver and spleen  - 
two major organs of the reticuloendothelial system (RES) 
(Zamboni 2005). Table 33 summarizes the accumulation of free 
and liposomal quercetin and vincistine in terms of Cma x and 
AUCl a s t .  For both quercetin and vincristine, the encapsulated 
drugs had higher AUCl a s t  levels as compared to free drugs. 
However, the Cma x values for the encapsulated drugs were lower 
as compared to free drugs.  
* * *
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Table 33 Accumulation of quercetin and vincristine in the liver 
and spleen after intravenous administration of free drug 
combination or the liposome co-encapsulated formulation. 
 
  Free Liposomal 
  Quercetin Vincrist ine Quercetin Vincrist ine
Liver 
Cma x  
(nmol/g) 0.66 1.27 0.05 1.60 
 
AUCl a s t  
(μmol.h/g) 4.68 2.70  4.30 16.00 
Spleen 
Cma x 
(nmol/g) 12.94 4.00 7.35 13.88 
 
AUCl a s t  
(μmol.h/g) 45.60 38.40 39.71 13.22 
Mice (n=4) received 1.33 mg/kg vincristine together with 0.24 
mg/kg quercetin (2:1 vincristine: quercetin molar ratio) as free 
forms or 1.33 mg/kg vincristine and 0.24 mg/kg quercetin co-
encapsulated into liposomes. Injection volumes were 200 μL. 
Pharmacokinetic parameters were obtained from the pooled data 
of 4 mice.    
 
 
9.2.3 In vivo antitumor effects against the JIMT-1 xenograft 
 
The antitumor efficacy against the JIMT-1 xenograft was 
evaluated by comparing (1) vehicle control,  (2) free quercetin, 
(3) free vincristine, (4) quercetin and vincristine combination in 
free form and (5) quercetin and vincristine co-encapsulated in 
liposomes. The dose of vincristine administered was 1.33 mg/kg, 
which was two-thirds of the maximum tolerated dose (MTD) of 
vincristine (Waterhouse, Madden et al.  2005) while the dose of 
quercetin was 0.24 mg/kg. This corresponded to a 
vincristine/quercetin molar ratio of 2:1. Figure 59 shows that 
although all  the treated groups (groups 2-5) showed initial tumor 
regression, only the liposomal quercetin and vincristine 
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treatment group maintained the tumor regression over the entire 
60 day period of the study.  
Table 34 shows the time taken for the different tumors to 
reach 500 mm3. One way ANOVA followed by post hoc Tukey 
analysis indicated that there was statistically significant 
difference between the liposomal quercetin and vincristine group 
and all  the other groups (p<0.05). In addition, the differences in 
tumor volume for both the free quercetin monotherapy and free 
vincristine monotherapy group were not statistically significant 
as compared to control (p>0.05). Table 34 also lists tumor 
growth inhibition, which showed trends similar to the time taken 
for the tumor to 500 mm3. According to the guidelines from the 
drug evaluation branch of the division of cancer treatment, 
National Cancer Institute considers tumor growth inhibition 
values equal or less than 42% as significant antitumor activity 
(Bissery, Guenard et al.  1991). Under this criterion, only the co-
encapsulated group exhibited significant antitumor activity. 
Percentage weight change at nadir was used as an indicator of 
the toxicity of the treatment (Laster, Schabel et  al .  1961).  
Statistical significance (p<0.05) was observed between the free 
quercetin and vincristine group as compared to the co-
encapsulated liposomal quercetin and vincristine group for the 
percentage weight change in nadir.  
Finally, Kaplan-meier survival analysis with log-rank 
significance test was conducted, as shown in Figure 59. 
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Statistical significance (p<0.05) was found between the co-
encapsulated liposomal quercetin and vincristine group with the 
following: (1) vehicle control group, (2) free quercetin group and 
(3) free vincristine group. There was no significant difference 
between the co-encapsulated liposomal vincristine/quercetin 
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Figure 59 In vivo  antitumor effects of the various treatment 
groups against JIMT-1 xenografts in SCID mice (n=5). The mice 
were treated via tail  vein injections with vehicle buffer (♦),  
quercetin (■),  vincristine (▲),  quercetin and vincristine as free 
form (x) and co-encapsulated quercetin and vincristine in 
liposomes (∆).  The doses of vincristine were 1.33 mg/kg and that 
of quercetin was 0.24 mg/kg (2:1 vincristine: quercetin mole 
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Table 34 Summary of in vivo antitumor efficacy studies in the 





Time taken for 
tumor to reach 
500 mm3 (days ± 
SD) 
Tumor growth 





Control 29.0 ± 3.4 NA 5.43 ± 0.28 
Free 
quercetin 
30.0 ± 1.2* 87 5.68 ± 0.55 
Free 
vincristine 










> 60 days* 
 
36 2.75 ± 0.37 
Co-encapsulated liposomal quercetin and vincristine showed
statistically significant difference between the liposomal
quercetin and vincristine group and all  the other groups, * p 
<0.05. 
aTumor growth inhibition = median tumor weight in the treated
group (T)/ median tumor weight in the control group (C) x 
100%. 
bPercentage weight change at nadir = (Initial weight before 
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Figure 60 Kaplan-meier survival curves of the different treatment 
groups over time (n=5), control (blue), free quercetin (pink), free 
vincristine (orange), free quercetin and vincristine combination 
(green), l iposomal quercetin and vincristine combination (purple).  
Log rank test was conducted.  
 
 
9.2.4 In vitro evaluation of CI values in the ratios of free quercetin and 
vincristine 
 
From  Section 9.2.1 ,  the ratios of vincristine/quercetin in 
plasma following the administration of free quercetin and 
vincristine were found to be 1:11, 1:12 and 1:6. The 
vincristine/quercetin ratios of 1:12 and 1:6 were tested in vitro  
and analyzed with the median-effect equation to determine CI. 
The CI values were 1.21 for the vincristine/quercetin ratio of 
1:12 and 2.41 for the vincristine/quercetin ratio 1:6, indicating 
antagonism when the two agents were administered freely in the 
absence of a drug carrier.   
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9.3 Discussion  
 
In this Chapter, it  has been shown that in the absence of a 
drug carrier,  the administration of free quercetin and vincristine 
led to antagonistic CIs in vivo .  This could potentially reduce the 
efficacy of antitumor therapy as antagonistic drug ratios were 
delivered from the blood to the tumor. The results highlighted 
the need for a delivery vehicle for optimal antitumor efficacy. In 
contrast, liposomal encapsulation of quercetin and vincristine 
prolonged circulation half l ife and co-ordinated the release of the 
agents, maintaining the most synergistic molar ratio of the two 
drugs both in vitro  and in vivo .  Importantly, it  was demonstrated 
that after liposomal co-encapsulation, enhanced antitumor 
efficacy could be achieved even at two-thirds the maximum 
tolerated dose (MTD) of vincristine, highlighting the potential of 
this formulation.   
Consistent with previous studies, the pharmacokinetic 
study showed that free vincristine and free quercetin had short 
half lives (Krishna, Webb et al.  2001; Yuan, Chen et al.  2006).  
After l iposomal incorporation, the in vivo  half life of quercetin 
was increased nine-fold to 14.2h as compared to free quercetin. 
In addition, this liposomal formulation also showed a seven-fold 
increment in terms of half l ife in vivo  as compared to a liposome 
formulation comprising of soybean lecithin, cholesterol and 
quercetin (Yuan, Chen et al.  2006).  A possible reason for this 
could be because ESM, the major component of the liposomes 
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used in the present study, forms a more rigid lipid bilayer as 
compared to that of soybean lecithin, thereby slowing down 
quercetin release (Hillery 2000).  
Similarly, liposomal encapsulation of vincristine increased 
its half life 30-fold to 16.0 h as compared to free vincristine. In 
addition, the formulation showed a four-fold increase in half l ife 
for vincristine as compared to DSPC/Cholesterol liposomes and 
around two-fold increase in half l ife as compared to 
ESM/Cholesterol l iposomes in vivo  (Krishna, Webb et al.  2001). 
This could be attributed to the liposomal bilayer rigidifying 
effect of quercetin through the formation of intermolecular 
hydrogen bonds (Tsuchiya, Nagayama et al .  2002), slowing down 
the release of vincristine from the liposomes. The higher Cma x, 
AUCt o t a l ,  t1 /2  and MRTl a s t  and lower Cl in liposomes as compared 
to free drug obtained was also consistent with prior studies 
involving liposomes (Webb, Logan et al. 1998; Yuan, Chen et al. 
2006).  
Finally, liposomal encapsulation also maintained the 
optimal synergistic ratio of vincristine/quercetin of 2:1 in plasma 
over the entire study period. Although liposomes had been shown 
to co-ordinate drug release previously, they involved only 
amphipathic or hydrophilic drugs (Mayer, Harasym et al.  2006; 
Tardi,  Gallagher et al.  2007; Tardi,  Johnstone et al.  2009). Our 
study is the first to co-ordinate the release of an amphipathic 
agent (vincristine) and hydrophobic agent (quercetin) in vivo .   
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A comparison of the AUC values between the plasma and 
the reticuloendothelial system (RES) comprising of the spleen 
and liver showed that the levels of quercetin and vincristine co-
encapsulated in the liposomes were lower in the RES as 
compared to that in plasma. This is consistent with other studies 
with liposomes formulated with PEG moiety, which reduced the 
rate of uptake of the liposomes by the RES (Allen and Stuart 
1999). The low levels of quercetin and vincristine detected in the 
RES is beneficial because the uptake by the RES leads to the 
irreversible sequestering of the encapsulated drug in the RES, 
preventing the drug from being exposed to the tumor (Zamboni 
2005). In addition, the uptake of the liposomes by the RES may 
result in acute impairment of the RES (Zamboni 2005); hence, 
the lower Cma x observed in the liposomal system as compared to 
free drug suggests that the RES is unlikely to be overwhelmed.  
Among the different treatment groups, the best antitumor 
activity was shown by co-encapsulated quercetin and vincristine, 
as reflected by the time taken for tumor to reach 500 mm3 and 
the tumor growth inhibition values. Under the criterion set by the 
drug evaluation branch of the division of cancer treatment, 
National Cancer Institute (Bissery, Guenard et al.  1991), only the 
co-encapsulated formulation exhibits significant antitumor 
activity. Taking the pharmacokinetic data together,  the increased 
antitumor efficacy in the co-encapsulated liposome group could 
be explained by (1) the longer circulation half life of quercetin 
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and vincristine increased the exposure duration of the tumor to 
the drugs resulting to an increase in antitumor activity (Jackson 
and Bender 1979; Horton, Houghton et al.  1988), (2) the optimal 
synergistic ratio of vincristine/quercetin of 2:1 was maintained 
in the plasma and to the tumor site. This was further supported 
by the antagonistic combination indices obtained from the 
administration of free quercetin and vincristine, which prevented 
the full synergistic potential to be realized. Importantly, this 
higher in vivo antitumor activity in the co-encapsulated 
liposomal formulation was attained even at two thirds of 
maximal tolerated dose of vincristine in SCID mice, which 
highlighted the potential of this formulation to achieve antitumor 
efficacy while reducing concentration dependent side effects.  In 
addition, Kaplan-meier survival analysis with log-rank 
significance test was conducted on the last day of the study on 
Day 60, to determine if there was any statistical difference in 
survival among the different groups. The log rank significance 
test  showed that there was no statistical difference between (1) 
the free vincristine/quercetin combination group and (2) the 
liposomal co-encapsulated quercetin and vincristine group. 
However, given that the tumor size of the free quercetin and 
vincristine group was double that of the co-encapsulated 
quercetin and vincristine liposome group, statistical difference 
might be attained if the study period was extended.  
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Finally, the percentage weight loss at nadir was used to 
evaluate the toxicity of the treatments (Corbett 2002). The 
percentage weight change between free quercetin and vincristine 
was statistically different (p < 0.05) as compared to that of 
liposomal quercetin and vincristine. Although higher levels of 
quercetin and vincristine were detected in the plasma and organs 
in the liposomal formulation as compared to free drug, this did 
not lead to an increase in toxicity. This could be explained by 
the high concentration of vincristine in plasma rather than the 
RES for the liposomal encapsulated group. In addition, given the 
short half life of quercetin and vincristine, most of the drug 
detected in plasma remained sequestered in the liposomes 
(Krishna, Webb et al.  2001), and were unable to exert their 
biological effects (Zamboni 2005; Lee, Kim et al.  2006), 
minimizing weight loss at nadir (Lee 2006).  
The study has shown that the co-encapsulation of 
vincristine/quercetin in liposomes at synergistic ratio showed 
good antitumor efficacy and low toxicity in an estrogen and 
progesterone receptor negative and transtuzumab insensitive 
xenograft model.  Importantly, enhanced antitumor efficacy could 
be achieved even at two-thirds the MTD of vincristine after 
liposomal incorporation.   
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C h a p t e r  1 0  
IMPLICATIONS, CONCLUSION AND FUTURE DIRECTIONS  
 
 
The implications of this work will be discussed from the 
formulation and clinical perspectives. From the formulation 
perspective, this is the first known attempt to co-encapsulate 
irinotecan and quercetin in a single drug carrier.  In spite of the 
anti-cancer synergy between irinotecan and quercetin reported in 
li terature (highlighted in Chapter 1),  this is the first  t ime that 
these two synergistic compounds has been co-encapsulated in a 
drug carrier.  This can enhance therapeutic efficacy by allowing 
controlled and co-ordinated release of the drug combination in 
their optimal synergistic ratio.  
Although quercetin and vincristine have been co-
encapsulated in nanoparticles (Song, Zhao et al.  2008), the 
present liposomal formulation coordinated the release of the two 
drugs which was otherwise not possible in the previous 
nanoparticle formulation. Coordinated release of quercetin and 
vincristine is crucial as the range of synergism between quercetin 
and vincristine is narrow, where a change from 
vincristine/quercetin molar ratio from 2:1 to 1:1 would lead to 
antagonism (Section 7.2.1). The present liposomal formulation is 
an improvement from the previous nanoparticle formulation as it  
coordinates the release of quercetin and vincristine from the 
liposomes to allow for optimal therapeutic efficacy to be exerted 
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between quercetin and vincristine, thereby a promising new 
therapeutic regimen against breast cancer.  
The coordinated release of drugs with drug delivery 
systems had been attempted in the past.  However, previous work 
had focused on the combination of conventional amphipathic 
chemotherapeutic drugs such as irinotecan with floxuridine 
(Tardi,  Gallagher et al.  2007), doxorubicin with vincristine 
(Abraham, McKenzie et al.  2004) and fludarabine with 
mitoxantrone (Zhao, Wu et al.  2007). This is the first  report 
which focused on the loading and coordinating the release of a 
hydrophobic substance, quercetin with amphipathic drugs such as 
vincristine and irinotecan, showing the feasibility of 
coordinating the release of hydrophobic and amphipathic drugs 
in liposomes.  
The research project has also shown that efficient loading 
of both hydrophobic and amphipathic compounds, having 
different requirements for efficient loading into liposomes, could 
be attained through optimization of formulation variables. This 
has been illustrated by the vincristine/quercetin combination. 
Quercetin incorporation and solubilization was found to be most 
efficient either in the absence or at  low levels of cholesterol but 
efficient and stable vincristine loading required at least 17.5 
mol% of cholesterol.  Finally, the formulation developed 
comprised of vincristine in Egg 
Sphingomyelin/Cholesterol/PEG2 000-ceramide/Quercetin 
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(72.5:17.5:5:5 mole ratio) liposomes and loading efficiency of 
both quercetin and vincristine were more than 70%. Moving 
forward, the combination of hydrophobic and amphipathic 
compounds are likely to become increasingly common because 
many of the new drug entities in the research pipeline are 
hydrophobic compounds and liposomes can potentially be used to 
co-encapsulate them. 
In addition, quercetin has been shown to alter vincristine 
release in the vincristine/quercetin liposomal formulation. It  
could be a novel alternative to alter drug loading and release 
profiles from liposomes. Besides traditional avenues to change 
drug loading and release, such as changing lipid composition, the 
formation of drug precipitates and changes in pH gradient,  the 
incorporation of quercetin or other compounds that can form 
hydrogen bonds represent a new avenue to alter drug loading and 
release. 
To our knowledge, this is the first attempt to load 
irinotecan in cholesterol free liposomes and also the first  
successful attempt in the use of temperatures above the phase 
transition temperature (Tc) of the lipid for drug loading in 
cholesterol free liposomes. Importantly, drug loading efficiency 
and time needed for the loading of irinotecan in cholesterol free 
liposomes were not significantly different from cholesterol 
containing liposomes. Previously, drug loading into cholesterol 
free liposomes have been limited to the use of temperatures 
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below Tc.  This has limited the utility of cholesterol free 
liposomes due to the longer drug loading times and lower drug: 
lipid ratio achievable as compared with conventional cholesterol 
containing liposomes. The project has indicated that efficient 
loading could potentially be attained in cholesterol free 
liposomes with the aid of a transmembrane gradient maintained 
by ionophore A23187 and could potentially be applied to other 
amphipathic chemotherapeutic drugs as well.   
From a clinical perspective, this work represents the first 
attempt to explore the use of quercetin and vincristine for HER2 
overexpressing breast cancer .  Currently, either high dose 
chemotherapy (Dizdar and Altundag 2010) or the combination of 
various chemotherapeutic agents (Chen and Russo 2009) are 
being used. However, these approaches either lacked therapeutic 
efficacy and failed to increase disease free survival (Heinemann 
2003) or were too toxic, leading to more treatment related deaths 
(Dizdar and Altundag 2010), thus highlighting the need to 
develop effective treatments. This work found that the co-
encapsulated liposome formulation exhibited significant 
antitumor activity at two-thirds of the maximum tolerated dose 
of vincristine and also showed less toxicity as compared to the 
free drug combination. Therefore, the formulation is efficacious 
and with reduced toxicity, which could have further clinical  
potential to be developed as a possible treatment avenue for 
HER2 overexpressing breast cancer.   
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In addition, the in vitro  data shows that the trends for 
synergistic and antagonistic ratios are similar against the two 
representative cell lines, JIMT-1 and MDA-MB-231. This could 
facilitate its clinical use as the same formulation is active 
against different cell lines, and is not specific to a particular 
subtype of breast cancer.  
Therefore, future studies that could be conducted include 
testing in more cell lines to verify whether the trends for synergy 
and antagonism are similar across different breast cancer cell  
l ines. In addition, this project has shown improved antitumor 
efficacy for the vincristine/quercetin liposomal formulation. The 
improved efficacy could be due to the maintenance of the 
synergistic ratio and the prolongation of half life. The extent of 
contribution by these two factors can be further determined by 
comparing the antitumor efficacy of liposomal quercetin alone, 
liposomal vincristine alone as well as an antagonistic ratio of 
vincristine/quercetin, 
From a broader perspective, future studies can be done to  
(1) Test the efficacy of this formulation against multidrug 
resistant cancers. 
Multidrug resistance-associated protein (MRP) has been 
implicated in multidrug resistant cancer, a major cause of cancer 
resistance. Since quercetin has been shown to inhibit 
chemotherapeutic drug efflux from the MRP (Leslie,  Mao et al.  
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2001), the liposomal formulation can be evaluated against MRP 
overexpressing cancer variants. 
(2) Formulate targeted liposomes. 
Liposomes can be attached with ligands against cell  
surface antigens so as to target the cancer cells.  This has the 
potential to increase therapeutic efficacy. Promising target 
ligands include epidermal growth factor receptor (EGFR), 
transferrin receptor and the folate receptor. These can be 
incorporated onto the liposomal formulations comprising of 
vincristine/quercetin or irinotecan/quercetin. In vivo  efficacy 
studies can be conducted to determine whether the ligands would 
enhance therapeutic efficacy.   
(3) Determine the molecular mechanisms contributing to the 
synergism exhibited by the vincristine/quercetin and 
irinotecan/quercetin combinations. 
The precise mechanism in which the drugs exhibit synergy 
in breast cancer cell  l ines remains unknown. Some possible 
targets to explore include tyrosine specific protein kinases, heat 
shock proteins and glycogen-synthase kinase-3-β ,  which have 
been shown to exhibit synergy in other cancer cell  l ines, as 
highlighted in the Chapter 1. It  is also of interest to explore if 
the ratio of chemotherapeutic drugs would have an impact on the 
expression of these factors.  
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